394 results on '"Fredrik Piehl"'
Search Results
52. Disrupted-in-schizophrenia 1 (DISC1) protein aggregates in cerebrospinal fluid are elevated in first-episode psychosis patients
- Author
-
Marlene Pils, Julia Rutsch, Feride Eren, Göran Engberg, Fredrik Piehl, Simon Cervenka, Carl Sellgren, Svenja Troßbach, Dieter Willbold, Sophie Erhardt, Oliver Bannach, and Carsten Korth
- Abstract
The Disrupted-in-schizophrenia 1 (DISC1) protein is a key regulator at the intersection of signaling pathways relevant for adaptive behavior. It is prone to posttranslational changes such as misassembly and aggregation but the significance of such transformations for human mental illness has remained unclear.Here we demonstrate that DISC1 protein aggregates are increased in CSF samples of patients with first episode psychosis (n=50) compared to healthy controls (n=47), as measured by the highly sensitive surface-based fluorescence intensity distribution analysis technology that enables single aggregate detection. The concentration was in the low femtomolar range. No correlations were found to symptom levels, but the difference was particularly significant in the subset of patients receiving the diagnoses “schizophrenia, unspecified” (DSM IV 295.9) or schizoaffective disorder (DSM IV 295.70) at 18-month follow-up.The occurrence of protein aggregatesin vivoin patients with psychotic disorders has not been previously reported. It underscores the significance of posttranslational modifications of proteins both as pathogenetic mechanisms and as potential diagnostic markers in these disorders.
- Published
- 2023
53. Proteomics profiling reveals biomarkers for predicting diagnosis, disease activity and long-term disability outcome in multiple sclerosis
- Author
-
Julia Åkesson, Sara Hojjati, Sandra Hellberg, Johanna Raffetseder, Mohsen Khademi, Robert Rynkowski, Ingrid Kockum, Claudio Altafini, Zelmina Lubovac-Pilav, Johan Mellergård, Maria Jenmalm, Fredrik Piehl, Tomas Olsson, Jan Ernerudh, and Mika Gustafsson
- Abstract
To personalize multiple sclerosis (MS) treatment strategies, sensitive and reliable protein biomarkers are needed to predict disease trajectory. We used protein profiling based on the highly sensitive proximity extension assay combined with next generation sequencing (Olink Explore) to measure 1463 proteins in cerebrospinal fluid (CSF) and plasma from 143 people with early-stage MS and 43 healthy controls. With longitudinally followed discovery and replication cohorts we identified CSF proteins that consistently predicted both short- and long-term disease progression. Neurofilament light chain (NfL) in CSF was confirmed as superior for predicting the absence of disease activity 2 years after sampling (replication AUC = 0.77). Importantly, we also identified a combination of 11 CSF proteins (CXCL13, LTA, FCN2, ICAM3, LY9, SLAMF7, TYMP, CHI3L1, FYB1, TNFRSF1B, NfL) that could predict the severity of disability worsening according to the normalized age-related MS severity score (replication AUC = 0.90). Identified proteins elucidate pathogenetic processes and can aid decisions of treatment strategies for people with MS.
- Published
- 2023
54. Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
- Author
-
Yihan Hu, Kejia Hu, Huan Song, Yudi Pawitan, Fredrik Piehl, and Fang Fang
- Subjects
Cellular and Molecular Neuroscience ,Psychiatry and Mental health ,Neurology ,Biological Psychiatry - Abstract
A link between neurodegenerative diseases and infections has been previously reported. However, it is not clear to what extent such link is caused by confounding factors or to what extent it is intimately connected with the underlying conditions. Further, studies on the impact of infections on mortality risk following neurodegenerative diseases are rare. We analysed two data sets with different characteristics: (i) a community-based cohort from the UK Biobank with 2023 patients with multiple sclerosis, 2200 patients with Alzheimer’s disease, 3050 patients with Parkinson’s disease diagnosed before 1 March 2020 and 5 controls per case who were randomly selected and individually matched to the case; (ii) a Swedish Twin Registry cohort with 230 patients with multiple sclerosis, 885 patients with Alzheimer’s disease and 626 patients with Parkinson’s disease diagnosed before 31 December 2016 and their disease-free co-twins. The relative risk of infections after a diagnosis of neurodegenerative disease was estimated using stratified Cox models, with adjustment for differences in baseline characteristics. Causal mediation analyses of survival outcomes based on Cox models were performed to assess the impact of infections on mortality. Compared with matched controls or unaffected co-twins, we observed an elevated infection risk after diagnosis of neurodegenerative diseases, with a fully adjusted hazard ratio (95% confidence interval) of 2.45 (2.24–2.69) for multiple sclerosis, 5.06 (4.58–5.59) for Alzheimer’s disease and 3.72 (3.44–4.01) for Parkinson’s disease in the UK Biobank cohort, and 1.78 (1.21–2.62) for multiple sclerosis, 1.50 (1.19–1.88) for Alzheimer’s disease and 2.30 (1.79–2.95) for Parkinson’s disease in the twin cohort. Similar risk increases were observed when we analysed infections during the 5 years before diagnosis of the respective disease. Occurrence of infections after diagnosis had, however, relatively little impact on mortality, as mediation of infections on mortality (95% confidence interval) was estimated as 31.89% (26.83–37.11%) for multiple sclerosis, 13.38% (11.49–15.29%) for Alzheimer’s disease and 18.85% (16.95–20.97%) for Parkinson’s disease in the UK Biobank cohort, whereas it was 6.56% (−3.59 to 16.88%) for multiple sclerosis, −2.21% (−0.21 to 4.65%) for Parkinson’s disease and −3.89% (−7.27 to −0.51%) for Alzheimer’s disease in the twin cohort. Individuals with studied neurodegenerative diseases display an increased risk of infections independently of genetic and familial environment factors. A similar magnitude of risk increase is present prior to confirmed diagnosis, which may indicate a modulating effect of the studied neurological conditions on immune defences.
- Published
- 2023
55. COVID-19–Related Enhancement for the COMBAT-MS Study
- Author
-
Fredrik Piehl, Anna Fogdell-Hahn, Simon Englund, Klara Asplund Högelin, Jessica Smith, Bonnie Li, Joachim Burman, Katharina Fink, Martin Gunnarsson, Jan Hillert, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Ingrid Kockum, Faiez Al Nimer, Elisa Longinetti, and Thomas Frisell
- Published
- 2023
56. The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors
- Author
-
David W. Nelson, Tobias Granberg, Pia Andersen, Elias Jokhadar, Jessica Kåhlin, Anna Granström, Helena Hallinder, Anna Schening, Charlotta Thunborg, Håkan Walles, Göran Hagman, Roya Shams‐Latifi, Jimmy Yu, Sven Petersson, Antonios Tzortzakakis, Nicholas Levak, Malin Aspö, Fredrik Piehl, Henrik Zetterberg, Miia Kivipelto, and Lars I. Eriksson
- Subjects
Anesthesiology and Pain Medicine ,Critical Care ,COVID-19 ,Humans ,Survivors ,General Medicine ,Pandemics ,Biomarkers - Abstract
This is the study plan of the Karolinska NeuroCOVID study, a study of neurocognitive impairment after severe COVID-19, relating post-intensive care unit (ICU) cognitive and neurological deficits to biofluid markers and MRI. The COVID-19 pandemic has posed enormous health challenges to individuals and health-care systems worldwide. An emerging feature of severe COVID-19 is that of temporary and extended neurocognitive impairment, exhibiting a myriad of symptoms and signs. The causes of this symptomatology have not yet been fully elucidated.In this study, we aim to investigate patients treated for severe COVID-19 in the ICU, as to describe and relate serum-, plasma- and cerebrospinal fluid-borne molecular and cellular biomarkers of immune activity, coagulopathy, cerebral damage, neuronal inflammation, and degeneration, to the temporal development of structural and functional changes within the brain as evident by serial MRI and extensive cognitive assessments at 3-12 months after ICU discharge.To date, we have performed 51 3-month follow-up MRIs in the ICU survivors. Of these, two patients (~4%) have had incidental findings on brain MRI findings requiring activation of the Incidental Findings Management Plan. Furthermore, the neuropsychological and neurological examinations have so far revealed varying and mixed patterns. Several patients expressed cognitive and/or mental concerns and fatigue, complaints closely related to brain fog.The study goal is to gain a better understanding of the pathological mechanisms and neurological consequences of this new disease, with a special emphasis on neurodegenerative and neuroinflammatory processes, in order to identify targets of intervention and rehabilitation.
- Published
- 2022
57. Demyelinating events following anti‐tumor necrosis factor alpha therapy: Rare but challenging to treat
- Author
-
Fredrik Piehl, Erik Kalén, and Magnus Andersson
- Subjects
Multiple Sclerosis ,Neurology ,Humans ,Neurology (clinical) ,Nervous System Diseases ,Magnetic Resonance Imaging ,Demyelinating Diseases ,Retrospective Studies - Abstract
Demyelinating events are listed as adverse events with tumor necrosis factor alpha inhibitors (TNFi), but epidemiological studies have provided partly conflicting risk estimates. Furthermore, studies examining long-term outcomes of demyelinating events associated with TNFi are rare.This was a retrospective, observational study comprising validation and tracking of long-term outcomes in patients referred to a tertiary neurology referral center for suspected neurological complications associated with TNFi.Of 48 patients evaluated, only 14 showed signs of demyelinating disease on magnetic resonance imaging, where six fulfilled criteria for a clinically isolated syndrome (CIS) and eight were diagnosed with multiple sclerosis (MS). However, 13 patients had received an International Classification of Diseases code for MS at some stage. Mean follow-up from referral was 13 and 10.5 years among subjects with MS and CIS, respectively. Continued disease activity was recorded among several of those fulfilling MS criteria, and two ultimately underwent autologous hematopoietic stem cell transplantation. In contrast, subjects with CIS showed no progression after cessation of TNFi.Our findings suggest that only a minority of those with suspected demyelinating disease following TNFi fulfill diagnostic criteria for MS and that MS diagnoses among those not fulfilling MS criteria may contribute to inflated epidemiological risk estimates. Nevertheless, in those fulfilling MS criteria, initiation of disease-modulating therapy, with escalation as needed, was important to suppress further disease activity.
- Published
- 2022
58. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
- Author
-
Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean-Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F Farez, Massimo Filippi, Kathryn C Fitzgerald, Mattia Fonderico, Riadh Gouider, Yael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frénay, Céline Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, María Isabel Zuluaga Rodas, Mar Tintoré, Bruno Stankoff, Tur, Carmen, Dubessy, Anne-Laure, Otero-Romero, Susana, Amato, Maria Pia, Derfuss, Tobia, Di Pauli, Franziska, Iacobaeus, Ellen, Mycko, Marcin, Abboud, Hesham, Achiron, Anat, Bellinvia, Angelo, Boyko, Alexey, Casanova, Jean-Laurent, Clifford, David, Dobson, Ruth, Farez, Mauricio F, Filippi, Massimo, Fitzgerald, Kathryn C, Fonderico, Mattia, Gouider, Riadh, Hacohen, Yael, Hellwig, Kerstin, Hemmer, Bernhard, Kappos, Ludwig, Ladeira, Filipa, Lebrun-Frénay, Christine, Louapre, Céline, Magyari, Melinda, Mehling, Matthia, Oreja-Guevara, Celia, Pandit, Lekha, Papeix, Caroline, Piehl, Fredrik, Portaccio, Emilio, Ruiz-Camps, Isabel, Selmaj, Krzysztof, Simpson-Yap, Steve, Siva, Aksel, Sorensen, Per Soelberg, Sormani, Maria Pia, Trojano, Maria, Vaknin-Dembinsky, Adi, Vukusic, Sandra, Weinshenker, Brian, Wiendl, Heinz, Winkelmann, Alexander, Zuluaga Rodas, María Isabel, Tintoré, Mar, and Stankoff, Bruno
- Subjects
SARS-CoV-2 ,Neuromyelitis Optica ,neuromyelitis optica spectrum disorder ,COVID-19 ,DMT-associated infections ,Multiple sclerosis ,coronavirus disease 2019 ,disease-modifying treatment ,progressive multifocal leukoencephalopathy ,risk mitigation strategies ,ddc ,Neurology ,Pregnancy ,Original Research Papers ,Humans ,Female ,Neurology (clinical) ,Child ,Pandemics - Abstract
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
- Published
- 2022
59. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
- Author
-
Koji Shinoda, Rui Li, Ayman Rezk, Ina Mexhitaj, Kristina R. Patterson, Mihir Kakara, Leah Zuroff, Jeffrey L. Bennett, H.-Christian von Büdingen, Robert Carruthers, Keith R. Edwards, Robert Fallis, Paul S. Giacomini, Benjamin M. Greenberg, David A. Hafler, Carolina Ionete, Ulrike W. Kaunzner, Christopher B. Lock, Erin E. Longbrake, Gabriel Pardo, Fredrik Piehl, Martin S. Weber, Tjalf Ziemssen, Dina Jacobs, Jeffrey M. Gelfand, Anne H. Cross, Briana Cameron, Bruno Musch, Ryan C. Winger, Xiaoming Jia, Christopher T. Harp, Ann Herman, and Amit Bar-Or
- Subjects
Multidisciplinary ,Multiple Sclerosis ,Mononuclear ,Neurosciences ,CD20dimCD8+ T cells ,CD8-Positive T-Lymphocytes ,Neurodegenerative ,Flow Cytometry ,anti-CD20 therapy ,Brain Disorders ,CD20dim T cells ,Recurrence ,ocrelizumab ,Leukocytes ,Humans ,2.1 Biological and endogenous factors ,CD20 ,Antigens ,Aetiology ,CD20-expressing T cells - Abstract
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of CD20-expressing cells with repeat infusions. We assessed cellular immune profiles and their association with transient disease activity following anti-CD20 initiation as a window into relapsing disease biology. Peripheral blood mononuclear cells from independent discovery and validation cohorts of MS patients initiating ocrelizumab were assessed for phenotypic and functional profiles using multiparametric flow cytometry. Pretreatment CD20-expressing T cells, especially CD20 dim CD8 + T cells with a highly inflammatory and central nervous system (CNS)-homing phenotype, were significantly inversely correlated with pretreatment MRI gadolinium-lesion counts, and also predictive of early disease activity observed after anti-CD20 initiation. Direct removal of pretreatment proinflammatory CD20 dim CD8 + T cells had a greater contribution to treatment-associated changes in the CD8 + T cell pool than was the case for CD4 + T cells. Early disease activity following anti-CD20 initiation was not associated with reconstituting CD20 dim CD8 + T cells, which were less proinflammatory compared with pretreatment. Similarly, this disease activity did not correlate with early reconstituting B cells, which were predominantly transitional CD19 + CD24 high CD38 high with a more anti-inflammatory profile. We provide insights into the mode-of-action of anti-CD20 and highlight a potential role for CD20 dim CD8 + T cells in MS relapse biology; their strong inverse correlation with both pretreatment and early posttreatment disease activity suggests that CD20-expressing CD8 + T cells leaving the circulation (possibly to the CNS) play a particularly early role in the immune cascades involved in relapse development.
- Published
- 2023
60. Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
- Author
-
David Leppert, Mitsuru Watanabe, Sabine Schaedelin, Fredrik Piehl, Roberto Furlan, Matteo Gastaldi, Jeremy Lambert, Björn Evertsson, Katharina Fink, Takuya Matsushita, Katsuhisa Masaki, Noriko Isobe, Jun-ichi Kira, Pascal Benkert, Aleksandra Maceski, Eline Willemse, Johanna Oechtering, Annette Orleth, Stephanie Meier, Jens Kuhle, and Neurochemistry Laboratory
- Subjects
Psychiatry and Mental health ,Surgery ,Neurology (clinical) - Abstract
BackgroundGranulocyte invasion into the brain is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). We aimed to determine whether granulocyte activation markers (GAM) in cerebrospinal fluid (CSF) can be used as a biomarker to distinguish NMOSD from MS, and whether levels associate with neurological impairment.MethodsWe quantified CSF levels of five GAM (neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin, matrixmetalloproteinase-8, tissue inhibitor of metalloproteinase-1), as well as a set of inflammatory and tissue-destruction markers, known to be upregulated in NMOSD and MS (neurofilament light chain, glial fibrillary acidic protein, S100B, matrix metalloproteinase-9, intercellular adhesion molecule-1, vascular cellular adhesion molecule-1), in two cohorts of patients with mixed NMOSD and relapsing-remitting multiple sclerosis (RRMS).ResultsIn acute NMOSD, GAM and adhesion molecules, but not the other markers, were higher than in RRMS and correlated with actual clinical disability scores. Peak GAM levels occurred at the onset of NMOSD attacks, while they were stably low in MS, allowing to differentiate the two diseases for ≤21 days from onset of clinical exacerbation. Composites of GAM provided area under the curve values of 0.90–0.98 (specificity of 0.76–1.0, sensitivity of 0.87–1.0) to differentiate NMOSD from MS, including all anti-aquaporin-4 protein (aAQP4)-antibody-negative patients who were untreated.ConclusionsGAM composites represent a novel biomarker to reliably differentiate NMOSD from MS, including in aAQP4−NMOSD. The association of GAM with the degree of concurrent neurological impairment provides evidence for their pathogenic role, in turn suggesting them as potential drug targets in acute NMOSD.
- Published
- 2023
61. Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity
- Author
-
Feride Eren, Lilly Schwieler, Funda Orhan, Anna Malmqvist, Fredrik Piehl, Simon Cervenka, Carl M. Sellgren, Helena Fatouros-Bergman, Göran Engberg, and Sophie Erhardt
- Subjects
schizophrenia ,Psychiatry ,Behavioral Neuroscience ,proteomics ,Endocrine and Autonomic Systems ,Immunology ,Immune markers ,chemokines ,cytokines ,Psykiatri - Abstract
Background and Hypothesis Immune activation is suggested to play an important role in psychosis. In this study, a large number of immune-related proteins were analyzed to obtain a more comprehensive picture of immune aberrations in schizophrenia. Study Design Ninety-two immune markers were analyzed by the Olink Protein Extension Assay (Inflammatory Panel) in plasma and cerebrospinal fluid (CSF) from 77 first-episode psychosis (FEP) patients (of which 43 later received the diagnosis of schizophrenia) and 56 healthy controls, all recruited from the Karolinska Schizophrenia Project (KaSP), Stockholm, Sweden. Study Results Differential analysis showed that 12 of 92 inflammatory proteins were significantly higher in the plasma of FEP patients (n = 77) than in controls, and several proteins were positively correlated with disease severity. Patients from the same cohort diagnosed with schizophrenia (n = 43), showed significantly higher levels of 15 plasma proteins compared to controls whereas those not receiving this diagnosis showed no significant differences. The presently used OLINK inflammatory panel allowed the detection of only 47 CSF proteins of which only CD5 differed between patients and controls. Conclusions The levels of several peripheral immune markers, particularly those interfering with WNT/β-catenin signaling, were significantly higher in patients with FEP than in healthy controls and associated with illness severity.
- Published
- 2023
62. Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
- Author
-
Kamila Zondra Revendova, Chiara Starvaggi Cucuzza, Ali Manouchehrinia, Mohsen Khademi, Michal Bar, David Leppert, Elisabeth Sandberg, Russell Ouellette, Tobias Granberg, and Fredrik Piehl
- Subjects
Behavioral Neuroscience - Abstract
Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics.We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41).Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ.In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.
- Published
- 2022
63. Author response for 'Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis'
- Author
-
null Kamila Zondra Revendova, null Chiara Starvaggi Cucuzza, null Ali Manouchehrinia, null Mohsen Khademi, null Michal Bar, null David Leppert, null Elisabeth Sandberg, null Russell Ouellette, null Tobias Granberg, and null Fredrik Piehl
- Published
- 2022
64. ECTRIMS 2021 – Oral Presentations
- Author
-
F. Al Nimer, Fredrik Piehl, Maja Jagodic, C. Starvaggi Cucuzza, Ingrid Kockum, T. Frisell, and Nicolas Ruffin
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Lymphocyte ,Multiple sclerosis ,Magnetic resonance imaging ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Neurology ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Rituximab ,Observational study ,Neurology (clinical) ,Dosing ,Analysis of variance ,business ,medicine.drug - Abstract
Introduction: B cell depletion with rituximab (RTX) is associated with high treatment efficacy in relapsing-remitting multiple sclerosis (RRMS), with low risk of rebound phenomena with treatment interruptions, but also increased risk of mainly bacterial infections. In order to reduce infection risks, further prompted by COVID19, RTX standard dosing intervals were extended up to 24 months in a single centre setting. Aims: To determine risk of disease flares in RRMS patients with extended RTX dosing intervals. Methods: We retrospectively analysed all RRMS patients (n=719) treated with RTX included in two ongoing observational drug trials, COMBAT-MS (EudraCT 2016-003587-39) and MultipleMS (2017-002634-24). Data were extracted from the Swedish MS registry for demographics, diagnosis, treatment history, clinical relapses and magnetic resonance imaging (MRI). Relapses and/or new MRI T2 lesions/contrast enhancing lesions, were recorded at first sign of clinical or MRI disease activity, or the lack thereof, at most recent visit/MRI for patients without signs of disease activity. The maximum interval (MI) between RTX doses before a registered outcome was used as a proxy for the efficacy of different treatment protocols. Results: Out of 697 patients with valid clinical data, 35 (5%) suffered a relapse, 19 of which occurred after the first RTX dose. Of the remainder, 13 patients had a relapse with a MI of 6±3 months (n=181, 7.2%), 3 with MI extended to 12±3 (n=313, 1%), and no relapse was found with MI of 18±3 or & gt;21 months (n=140 and n=63, respectively). MRI activity was detected in 54/572 subjects (including 6 after first dose), of which 24/152 (15,8%) with MI 6±3 month, 16/244 (6.5%) with MI of 12±3 months, 9/116 (7.8%) with MI of 18±3 months and 5/60 (8.3%) with MI of & gt;21 months. No major differences were found among the four groups concerning demographics, type of prior treatment and disability, except for a lower number of RTX doses in the 6±3 month MI group (mean number of RTX doses 3.3, 5.8, 6.8 and 6.1, respectively;ANOVA p
- Published
- 2021
65. B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis
- Author
-
Can Ulutekin, Edoardo Galli, Mohsen Khademi, Ilaria Callegari, Fredrik Piehl, Nicholas Sanderson, Massimo Filippi, Roberto Furlan, Tomas Olsson, Tobias Derfuss, Florian Ingelfinger, and Burkhard Becher
- Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). Traditionally, MS was held to be a T-cell mediated disease, but accumulating evidence during the last decade also highlighted the crucial importance of B cells for the disease progression. Particularly, B cell depleting therapies (BCDTs), have demonstrated striking efficacy in suppressing inflammatory disease activity in relapsing-remitting MS. However, a detailed understanding of the role of B cells in the pathogenesis of MS is still lacking, and by extension also the mechanism of action of BCDTs. In this longitudinal multi-center study, we investigated the impact of BCDTs on the immune landscape in MS patients using high-dimensional single-cell immunophenotyping (cytometry by time-of-flight; CyTOF). Algorithm-guided analyses revealed phenotypic changes in the newly reconstituted B cell compartment after BCDT, as well as a marked specific reduction of circulating T follicular helper (Tfh) cells with a concomitant upregulation of CD27 surface expression in memory T helper cells and Tfh cells. These findings indicate a costimulatory mechanism in the CD27/CD70 signaling pathway, through which B cells sustain the activation of pathogenic T cells. Disrupting the CD27/CD70 signaling axis via BCDTs provides a potential explanation for its clinical efficacy.One Sentence SummaryB cell depletion contracts follicular T helper cells, displaces memory-to-naïve ratio and impairs CD27 signaling in T helper cells.
- Published
- 2022
66. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study
- Author
-
Fredrik Piehl, Rayomand Press, Fang Fang, Elisa Longinetti, Weimin Ye, Olafur Sveinsson, and Caroline Ingre
- Subjects
Male ,Sweden ,medicine.medical_specialty ,Riluzole ,business.industry ,Multiple sclerosis ,Medical record ,Amyotrophic Lateral Sclerosis ,medicine.disease ,Myasthenia gravis ,Neurology ,Internal medicine ,Myasthenia Gravis ,Neuroinflammatory Diseases ,medicine ,Humans ,Female ,Bulbar onset ,Neurology (clinical) ,Medical diagnosis ,Amyotrophic lateral sclerosis ,business ,Clinical record ,medicine.drug - Abstract
Objective:To determine if inflammation in proximity of the motor unit may contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS). Methods: We identified all patients diagnosed in Sweden with concurrent ALS and multiple sclerosis (MS), myasthenia gravis (MG), inflammatory polyneuropathies (IP), or dermatopolymyositis (DMPM) during 1991-2014 according to the Swedish Patient Register (N = 263). We validated medical records for 92% of these patients (18 records were not retrieved and three did not contain enough information) and compared patients with a confirmed overlap (N = 28) with an independent sample of patients with solely ALS (N = 271). Results: Ninety-one patients were deemed as not having ALS (34.6%). Among the remaining 151 with validated ALS, 12 had also a confirmed MS diagnosis, nine a confirmed MG diagnosis, four a confirmed IP diagnosis, and three a confirmed DMPM diagnosis. Seventeen of the patients were women and 11 were men. Seventy-nine percent of the patients with a confirmed overlap had MS, MG, IP, or DMPM diagnosed prior to ALS. Compared to patients with only ALS, the concurrent patients were significantly older at symptoms onset, had higher prevalence of bulbar onset, but used Riluzole and noninvasive ventilation less frequently. Conclusions: We found that a high concurrence of ALS and MS/MG/IP/DMPM diagnoses is largely due to diagnostic uncertainty. A minority of patients had a true concurrence, where MS, MG, IP, and DMPM preceded the ALS diagnosis, which might be due to chance alone. Four patients were diagnosed with MG shortly after onset of ALS, suggesting that neurodegeneration might trigger autoimmunity.
- Published
- 2021
67. Plasma protein profiling of multiple sclerosis using proximity extension assays
- Author
-
Jesse Huang, Mohsen Khademi, Fredrik Piehl, Tomas Olsson, and Ingrid Kockum
- Abstract
BackgroundMultiple sclerosis (MS) is an inflammatory disease characterized by demyelination and neuro-axonal degeneration in the central nervous system. Except for neurofilament light protein, identification of biomarkers has been difficult to assess in the blood, presumably due partly to sensitivity. To detect traces of disease activities in the periphery and identify low-abundance protein biomarkers, this study conducts an exploratory examination of the plasma proteome of MS using proximity extension technology, a high-sensitivity multiplex PCR-based immunoassay.MethodsA case-control cohort consisting of 52 MS cases (relapsing-remitting=30, progressive=22) and 17 healthy controls were enrolled at the Karolinska University Hospital. EDTA plasma was analyzed for 1157 unique protein targets across thirteen proximity extension assays. Protein associations to disease outcomes and related clinical measures were assessed using a multivariable linear regression model corrected for sex and age at sampling.ResultsAHCY and CHR levels were higher among MS cases than controls, while FABP2 was lower among those with relapsing-remitting disease than controls (PdiscoveryreplicationFDRFDR−5, PFDR=0.044), while RRM2B level correlated with intrathecal immunoglobulin production (IgG Index) in relapsing-remitting MS (P=1.7×10−5, PFDR=0.018).ConclusionWe provide several candidates for characterizing MS, particularly progressive disease, which may help monitor disease progression and treatment response in a clinical setting.
- Published
- 2022
68. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
- Author
-
Chiara, Starvaggi Cucuzza, Elisa, Longinetti, Nicolas, Ruffin, Björn, Evertsson, Ingrid, Kockum, Maja, Jagodic, Faiez, Al Nimer, Thomas, Frisell, and Fredrik, Piehl
- Subjects
Multiple Sclerosis ,Multiple Sclerosis, Relapsing-Remitting ,Recurrence ,Chronic Disease ,Humans ,Immunologic Factors ,Prospective Studies ,Rituximab - Abstract
B cell-depleting therapies are highly effective in relapsing-remitting multiple sclerosis (RRMS) but are associated with increased infection risk and blunted humoral vaccination responses. Extension of dosing intervals may mitigate such negative effects, but its consequences on MS disease activity are yet to be ascertained. The objective of this study was to determine clinical and neuroradiologic disease activity, as well as B-cell repopulation dynamics, after implementation of extended rituximab dosing in RRMS.We conducted a prospective observational study in a specialized-care, single-center setting, including patients with RRMS participating in the COMBAT-MS and MultipleMS observational drug trials, who had received at least 2 courses of rituximab (median follow-up 4.2 years, range 0.1-8.9 years). Using Cox regression, hazard ratios (HRs) of clinical relapse and/or contrast-enhancing lesions on MRI were calculated in relation to time since last dose of rituximab.A total of 3,904 dose intervals were accumulated in 718 patients and stratified into 4 intervals:8, ≥8 to 12, ≥12 to 18, and ≥18 months. We identified 24 relapses of which 20 occurred within 8 months since previous infusion and 4 with intervals over 8 months. HRs for relapse when comparing ≥8 to 12, ≥12 to 18, and ≥18 months with8 months since last dose were 0.28 (95% CI 0.04-2.10), 0.38 (95% CI 0.05-2.94), and 0.89 (95% CI 0.20-4.04), respectively, and thus nonsignificant. Neuroradiologic outcomes mirrored relapse rates. Dynamics of total B-cell reconstitution varied considerably, but median total B-cell counts reached lower level of normal after 12 months and median memory B-cell counts after 16 months.In this prospective cohort of rituximab-treated patients with RRMS exposed to extended dosing intervals, we could not detect a relation between clinical or neuroradiologic disease activity and time since last infusion. Total B- and memory B-cell repopulation kinetics varied considerably. These findings, relevant for assessing risk-mitigation strategies with anti-CD20 therapies in RRMS, suggest that relapse risk remains low with extended infusion intervals. Further studies are needed to investigate the relation between B-cell repopulation dynamics and adverse event risks associated with B-cell depletion.
- Published
- 2022
69. Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
- Author
-
Ayako Hiyoshi, Tomas Olsson, Scott Montgomery, Kelsi A Smith, Yin Xu, and Fredrik Piehl
- Subjects
Male ,Risk ,Pediatrics ,medicine.medical_specialty ,Multiple Sclerosis ,Adolescent ,Mononucleosis ,Infections ,Young Adult ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Humans ,Medicine ,Registries ,030212 general & internal medicine ,Medical diagnosis ,Child ,Sweden ,business.industry ,Proportional hazards model ,Multiple sclerosis ,Hazard ratio ,Age Factors ,Respiratory infection ,medicine.disease ,Confidence interval ,Pneumonia ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
The involvement of specific viral and bacterial infections as risk factors for multiple sclerosis has been studied extensively. However, whether this extends to infections in a broader sense is less clear and little is known about whether risk of a multiple sclerosis diagnosis is associated with other types and sites of infections such as the CNS. This study aims to assess if hospital-diagnosed infections by type and site before age 20 years are associated with risk of a subsequent multiple sclerosis diagnosis and whether this association is explained entirely by infectious mononucleosis, pneumonia, and CNS infections. Individuals born in Sweden between 1970 and 1994 were identified using the Swedish Total Population Register (n = 2 422 969). Multiple sclerosis diagnoses from age 20 years and hospital-diagnosed infections before age 20 years were identified using the Swedish National Patient Register. Risk of a multiple sclerosis diagnosis associated with various infections in adolescence (11–19 years) and earlier childhood (birth–10 years) was estimated using Cox regression, with adjustment for sex, parental socio-economic position, and infection type. None of the infections by age 10 years were associated with risk of a multiple sclerosis diagnosis. Any infection in adolescence increased the risk of a multiple sclerosis diagnosis (hazard ratio 1.33, 95% confidence interval 1.21–1.46) and remained statistically significant after exclusion of infectious mononucleosis, pneumonia, and CNS infection (hazard ratio 1.17, 95% confidence interval 1.06–1.30). CNS infection in adolescence (excluding encephalomyelitis to avoid including acute disseminated encephalitis) increased the risk of a multiple sclerosis diagnosis (hazard ratio 1.85, 95% confidence interval 1.11–3.07). The increased risk of a multiple sclerosis diagnosis associated with viral infection in adolescence was largely explained by infectious mononucleosis. Bacterial infections in adolescence increased risk of a multiple sclerosis diagnosis, but the magnitude of risk reduced after excluding infectious mononucleosis, pneumonia and CNS infection (hazard ratio 1.31, 95% confidence interval 1.13–1.51). Respiratory infection in adolescence also increased risk of a multiple sclerosis diagnosis (hazard ratio 1.51, 95% confidence interval 1.30–1.75), but was not statistically significant after excluding infectious mononucleosis and pneumonia. These findings suggest that a variety of serious infections in adolescence, including novel evidence for CNS infections, are risk factors for a subsequent multiple sclerosis diagnosis, further demonstrating adolescence is a critical period of susceptibility to environmental exposures that raise the risk of a multiple sclerosis diagnosis. Importantly, this increased risk cannot be entirely explained by infectious mononucleosis, pneumonia, or CNS infections.
- Published
- 2021
70. Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS
- Author
-
Alessandra Solari, Xavier Montalban, Jeannette Lechner-Scott, Fredrik Piehl, Bruno Brochet, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Eva K. Havrdova, Francesco Patti, Luis Brieva, Eva Maria Maida, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Birgit Keller, and null on behalf of the CLARIFY-MS Investigators
- Subjects
Neurology ,Neurology (clinical) ,General Medicine - Published
- 2023
71. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort
- Author
-
Malin, Petersson, Amalia, Feresiadou, Daniel, Jons, Andreea, Ilinca, Fredrik, Lundin, Rune, Johansson, Anna, Budzianowska, Anna-Karin, Roos, Viktor, Kågström, Martin, Gunnarsson, Peter, Sundström, Fredrik, Piehl, and Susanna, Brauner
- Subjects
Pediatrics ,medicine.medical_specialty ,Cross-sectional study ,business.industry ,Symptom severity ,Correction ,medicine.disease ,Myasthenia gravis ,Cohort ,Medicine ,Neurology (clinical) ,business ,Research Article - Abstract
Background and Objectives To describe myasthenia gravis activities of daily living (MG-ADL) in relation to clinical characteristics in a large Swedish nationwide cohort. Methods In a cross-sectional prevalence cohort study, the Genes and Environment in Myasthenia Gravis study, performed from November 2018 through August 2019, patients with myasthenia gravis (MG) were invited to submit an extensive 106-item life environment questionnaire, including the MG-ADL score. Patients were classified into early-onset MG (EOMG
- Published
- 2021
72. Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
- Author
-
Fredrik Piehl
- Subjects
0301 basic medicine ,Multiple Sclerosis ,Reviews ,Review ,Disease ,030204 cardiovascular system & hematology ,Bioinformatics ,benefit‐risk ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal Medicine ,medicine ,Humans ,biologics ,Remyelination ,Cladribine ,Clinical Trials as Topic ,business.industry ,Multiple sclerosis ,medicine.disease ,Clinical trial ,remyelination ,030104 developmental biology ,medicine.anatomical_structure ,Drug class ,Tolerability ,randomized controlled trial ,immunomodulatory therapy ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
The treatment of multiple sclerosis (MS), the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS), continues to transform. In recent years, a number of novel and increasingly effective disease‐modulatory therapies (DMTs) have been approved, including oral fumarates and selective sphingosine 1‐phosphate modulators, as well as cell‐depleting therapies such as cladribine, anti‐CD20 and anti‐CD52 monoclonals. Amongst DMTs in clinical development, inhibitors of Bruton's tyrosine kinase represent an entirely new emerging drug class in MS, with three different drugs entering phase III trials. However, important remaining fields of improvement comprise tracking of long‐term benefit‐risk with existing DMTs and exploration of novel treatment targets relating to brain inherent disease processes underlying the progressive neurodegenerative aspect of MS, which accumulating evidence suggests start already early in the disease process. The aim here is to review current therapeutic options in relation to an improved understanding of the immunopathogenesis of MS, also highlighting examples where controlled trials have not generated the desired results. An additional aim is to review emerging therapies undergoing clinical development, including agents that interfere with disease processes believed to be important for neurodegeneration or aiming to enhance reparative responses. Notably, early trials now have shown initial evidence of enhanced remyelination both with small molecule compounds and biologicals. Finally, accumulating evidence from clinical trials and post‐marketing real‐world patient populations, which underscore the importance of early high effective therapy whilst maintaining acceptable tolerability, is discussed.
- Published
- 2020
73. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
- Author
-
Mantegazza, R., Wolfe, G. I., Muppidi, S., Wiendl, H., Fujita, K. P., O'Brien, F. L., Booth, H. D. E., Howard, J. F., Claudio Gabriel Mazia, Miguel, Wilken, Fabio, Barroso, Juliet, Saba, Marcelo, Rugiero, Mariela, Bettini, Marcelo, Chaves, Gonzalo, Vidal, Alejandra Dalila Garcia, Jan De Bleecker, Guy Van den Abeele, Kathy de Koning, Katrien De Mey, Rudy, Mercelis, Délphine, Mahieu, Linda, Wagemaekers, Philip Van Damme, Annelies, Depreitere, Caroline, Schotte, Charlotte, Smetcoren, Olivier, Stevens, Sien Van Daele, Nicolas, Vandenbussche, Annelies, Vanhee, Sarah, Verjans, Jan, Vynckier, Ann, D'Hont, Petra, Tilkin, Alzira Alves de Siqueira Carvalho, Igor Dias Brockhausen, David, Feder, Daniel, Ambrosio, Gabor Lovasamela César, Ana Paula Melo, Renata Martins Ribeiro, Rosana, Rocha, Bruno Bezerra Rosa, Thabata, Veiga, Luiz Augusto da Silva, Murilo Santos Engel, Jordana Gonçalves Geraldo, Maria da Penha Ananias Morita, Erica Nogueira Coelho, Gabriel, Paiva, Marina, Pozo, Natalia, Prando, Debora Dada Martineli Torres, Cristiani Fernanda Butinhao, Gustavo, Duran, Tomás Augusto Suriane Fialho, Tamires Cristina Gomes da Silva, Luiz Otavio Maia Gonçalves, Lucas Eduardo Pazetto, Luciana Renata Cubas Volpe, Luciana Souza Duca, Maurício AndréGheller Friedrich, Alexandre, Guerreiro, Henrique, Mohr, Maurer Pereira Martins, Daiane da Cruz Pacheco, Luciana, Ferreira, Ana Paula Macagnan, Graziela, Pinto, Aline de Cassia Santos, Acary Souza Bulle Oliveira, Ana Carolina Amaral de Andrade, Marcelo, Annes, Liene Duarte Silva, Valeria Cavalcante Lino, Wladimir, Pinto, Natália, Assis, Fernanda, Carrara, Carolina, Miranda, Iandra, Souza, Patrícia, Fernandes, Zaeem, Siddiqi, Cecile, Phan, Jeffrey, Narayan, Derrick, Blackmore, Ashley, Mallon, Rikki, Roderus, Elizabeth, Watt, Stanislav, Vohanka, Josef, Bednarik, Magda, Chmelikova, Marek, Cierny, Stanislava, Toncrova, Jana, Junkerova, Barbora, Kurkova, Katarina, Reguliova, Olga, Zapletalova, Jiri, Pitha, Iveta, Novakova, Michaela, Tyblova, Ivana, Jurajdova, Marcela, Wolfova, Henning, Andersen, Thomas, Harbo, Lotte, Vinge, Susanne, Krogh, Anita, Mogensen, John, Vissing, Joan, Højgaard, Nanna, Witting, Anne Mette Ostergaard Autzen, Jane, Pedersen, Juha-Pekka, Erälinna, Mikko, Laaksonen, Olli, Oksaranta, Tuula, Harrison, Jaana, Eriksson, Csilla, Rozsa, Melinda, Horvath, Gabor, Lovas, Judit, Matolcsi, Gedeonne, Jakab, Gyorgyi, Szabo, Brigitta, Szabadosne, Laszlo, Vecsei, Livia, Dezsi, Edina, Varga, Monika, Konyane, Antonini, Giovanni, Antonella Di Pasquale, Garibaldi, Matteo, Morino, Stefania, Troili, Fernanda, Fionda, Laura, Amelia, Evoli, Paolo Emilio Alboini, Valentina, D'Amato, Raffaele, Iorio, Inghilleri, Maurizio, Frasca, Vittorio, Elena, Giacomelli, Gori, MARIA CRISTINA, Diego, Lopergolo, Onesti, Emanuela, Maria, Gabriele, Francesco, Saccà, Alessandro, Filla, Teresa, Costabile, Enrico, Marano, Angiola, Fasanaro, Angela, Marsili, Giorgia, Puorro, Carlo, Antozzi, Silvia, Bonanno, Giorgia, Camera, Alberta, Locatelli, Lorenzo, Maggi, Maria, Pasanisi, Angela, Campanella, Akiyuki, Uzawa, Tetsuya, Kanai, Naoki, Kawaguchi, Masahiro, Mori, Yoko, Kaneko, Akiko, Kanzaki, Eri, Kobayashi, Hiroyuki, Murai, Katsuhisa, Masaki, Dai, Matsuse, Takuya, Matsushita, Taira, Uehara, Misa, Shimpo, Maki, Jingu, Keiko, Kikutake, Yumiko, Nakamura, Yoshiko, Sano, Kimiaki, Utsugisawa, Yuriko, Nagane, Ikuko, Kamegamori, Tomoko, Tsuda, Yuko, Fujii, Kazumi, Futono, Yukiko, Ozawa, Aya, Mizugami, Yuka, Saito, Makoto, Samukawa, Hidekazu, Suzuki, Miyuki, Morikawa, Sachiko, Kamakura, Eriko, Miyawaki, Meinoshin, Okumura, Soichiro, Funaka, Tomohiro, Kawamura, Masayuki, Nakamori, Masanori, Takahashi, Namie, Taichi, Tomoya, Hasuike, Eriko, Higuchi, Hisako, Kobayashi, Kaori, Osakada, Hirokazu, Shiraishi, Teiichiro, Miyazaki, Masakatsu, Motomura, Akihiro, Mukaino, Shunsuke, Yoshimura, Shizuka, Asada, Seiko, Yoshida, Shoko, Amamoto, Tomomi, Kobashikawa, Megumi, Koga, Maeda, Yasuko, Kazumi, Takada, Mihoko, Takada, Masako, Tsurumaru, Yumi, Yamashita, Yasushi, Suzuki, Tetsuya, Akiyama, Koichi, Narikawa, Ohito, Tano, Kenichi, Tsukita, Rikako, Kurihara, Fumie, Meguro, Yusuke, Fukuda, Miwako, Sato, Tomihiro, Imai, Emiko, Tsuda, Shun, Shimohama, Takashi, Hayashi, Shin, Hisahara, Jun, Kawamata, Takashi, Murahara, Masaki, Saitoh, Shuichiro, Suzuki, Daisuke, Yamamoto, Yoko, Ishiyama, Naoko, Ishiyama, Mayuko, Noshiro, Rumi, Takeyama, Kaori, Uwasa, Ikuko, Yasuda, Anneke van der Kooi, Marianne de Visser, Tamar, Gibson, Byung-Jo, Kim, Chang Nyoung Lee, Yong Seo Koo, Hung Youl Seok, Hoo Nam Kang, Hyejin, Ra, Byoung Joon Kim, Eun Bin Cho, Misong, Choi, Hyelim, Lee, Ju-Hong, Min, Jinmyoung, Seok, Jieun, Lee, Da Yoon Koh, Juyoung, Kwon, Sangae, Park, Eun Haw Choi, Yoon-Ho, Hong, So-Hyun, Ahn, Dae Lim Koo, Jae-Sung, Lim, Chae Won Shin, Ji Ye Hwang, Miri, Kim, Seung Min Kim, Ha-Neul, Jeong, Jinwoo, Jung, Yool-Hee, Kim, Hyung Seok Lee, Ha Young Shin, Eun Bi Hwang, Miju, Shin, Carlos, Casasnovas, Maria Antonia Alberti Aguilo, Christian, Homedes-Pedret, Natalia Julia Palacios, Laura Diez Porras, Valentina Velez Santamaria, Ana, Lazaro, Josep Gamez Carbonell, Pilar, Sune, Maria Salvado Figueras, Gisela, Gili, Gonzalo, Mazuela, Isabel, Illa, Elena Cortes Vicente, Jordi, Diaz-Manera, Luis Antonio Querol Gutiérrez, Ricardo Rojas Garcia, Nuria, Vidal, Elisabet, Arribas-Ibar, Exuperio Diez Tejedor, Pilar Gomez Salcedo, Mireya, Fernandez-Fournier, Pedro Lopez Ruiz, Francisco Javier Rodriguez de Rivera, Maria, Sastre, Fredrik, Piehl, Albert, Hietala, Lena, Bjarbo, Ihsan, Sengun, Arzu, Meherremova, Pinar, Ozcelik, Bengu, Balkan, Celal, Tuga, Muzeyyen, Ugur, Sevim, Erdem-Ozdamar, Can Ebru Bekircan-Kurt, Nazire Pinar Acar, Ezgi, Yilmaz, Yagmur, Caliskan, Gulsah, Orsel, Husnu, Efendi, Seda, Aydinlik, Hakan, Cavus, Ayse, Kutlu, Gulsah, Becerikli, Cansu, Semiz, Ozlem, Tun, Murat, Terzi, Baki, Dogan, Musa Kazim Onar, Sedat, Sen, Tugce Kirbas Cavdar, Adife, Veske, Fiona, Norwood, Aikaterini, Dimitriou, Jakit, Gollogly, Mohamed, Mahdi-Rogers, Arshira, Seddigh, Giannis, Sokratous, Gal, Maier, Faisal, Sohail, Saiju, Jacob, Girija, Sadalage, Pravin, Torane, Claire, Brown, Amna, Shah, Sivakumar, Sathasivam, Heike, Arndt, Debbie, Davies, Dave, Watling, Anthony, Amato, Thomas, Cochrane, Mohammed, Salajegheh, Kristen, Roe, Katherine, Amato, Shirli, Toska, Nicholas, Silvestri, Kara, Patrick, Karen, Zakalik, Jonathan, Katz, Robert, Miller, Marguerite, Engel, Dallas, Forshew, Elena, Bravver, Benjamin, Brooks, Mohammed, Sanjak, Sarah, Plevka, Maryanne, Burdette, Scott, Cunningham, Megan, Kramer, Joanne, Nemeth, Clara, Schommer, Tierney, Scott, Vern, Juel, Jeffrey, Guptill, Lisa, Hobson-Webb, Janice, Massey, Kate, Beck, Donna, Carnes, John, Loor, Amanda, Anderson, Robert, Pascuzzi, Cynthia, Bodkin, John, Kincaid, Riley, Snook, Sandra, Guingrich, Angela, Micheels, Vinay, Chaudhry, Andrea, Corse, Betsy, Mosmiller, Andrea, Kelley, Doreen, Ho, Jayashri, Srinivasan, Michal, Vytopil, Jordan, Jara, Nicholas, Ventura, Cynthia, Carter, Craig, Donahue, Carol, Herbert, Stephanie, Scala, Elaine, Weiner, Sharmeen, Alam, Jonathan, Mckinnon, Laura, Haar, Naya, Mckinnon, Karan, Alcon, Kaitlyn, Mckenna, Nadia, Sattar, Kevin, Daniels, Dennis, Jeffery, Miriam, Freimer, Joseph Chad Hoyle, John, Kissel, Julie, Agriesti, Sharon, Chelnick, Louisa, Mezache, Colleen, Pineda, Filiz, Muharrem, Chafic, Karam, Julie, Khoury, Tessa, Marburger, Harpreet, Kaur, Diana, Dimitrova, James, Gilchrist, Brajesh, Agrawal, Mona, Elsayed, Stephanie, Kohlrus, Angela, Ardoin, Taylor, Darnell, Laura, Golden, Barbara, Lokaitis, Jenna, Seelbach, Neelam, Goyal, Sarada, Sakamuri, Yuen, T So, Shirley, Paulose, Sabrina, Pol, Lesly, Welsh, Ratna, Bhavaraju-Sanka, Alejandro Tobon Gonzalez, Lorraine, Dishman, Floyd, Jones, Anna, Gonzalez, Patricia, Padilla, Amy, Saklad, Marcela, Silva, Sharon, Nations, Jaya, Trivedi, Steve, Hopkins, Mohamed, Kazamel, Mohammad, Alsharabati, Liang, Lu, Kenkichi, Nozaki, Sandi, Mumfrey-Thomas, Amy, Woodall, Tahseen, Mozaffar, Tiyonnoh, Cash, Namita, Goyal, Gulmohor, Roy, Veena, Mathew, Fatima, Maqsood, Brian, Minton, H James Jones, Jeffrey, Rosenfeld, Rebekah, Garcia, Laura, Echevarria, Sonia, Garcia, Michael, Pulley, Shachie, Aranke, Alan Ross Berger, Jaimin, Shah, Yasmeen, Shabbir, Lisa, Smith, Mary, Varghese, Laurie, Gutmann, Ludwig, Gutmann, Nivedita, Jerath, Christopher, Nance, Andrea, Swenson, Heena, Olalde, Nicole, Kressin, Jeri, Sieren, Richard, Barohn, Mazen, Dimachkie, Melanie, Glenn, April, Mcvey, Mamatha, Pasnoor, Jeffery, Statland, Yunxia, Wang, Tina, Liu, Kelley, Emmons, Nicole, Jenci, Jerry, Locheke, Alex, Fondaw, Kathryn, Johns, Gabrielle, Rico, Maureen, Walsh, Laura, Herbelin, Charlene, Hafer-Macko, Justin, Kwan, Lindsay, Zilliox, Karen, Callison, Valerie, Young, Beth, Disanzo, Kerry, Naunton, Michael, Benatar, Martin, Bilsker, Khema, Sharma, Anne, Cooley, Eliana, Reyes, Sara-Claude, Michon, Danielle, Sheldon, Julie, Steele, Rebecca, Traub, Manisha, Chopra, Tuan, Vu, Lara, Katzin, Terry, Mcclain, Brittany, Harvey, Adam, Hart, Kristin, Huynh, Said, Beydoun, Amaiak, Chilingaryan, Victor, Doan, Brian, Droker, Hui, Gong, Sanaz, Karimi, Frank, Lin, Krishna, Polaka, Akshay, Shah, Anh, Tran, Salma, Akhter, Ali, Malekniazi, Rup, Tandan, Michael, Hehir, Waqar, Waheed, Shannon, Lucy, Michael, Weiss, Jane, Distad, Susan, Strom, Sharon, Downing, Bryan, Kim, Tulio, Bertorini, Thomas, Arnold, Kendrick, Henderson, Rekha, Pillai, Liu, Ye, Lauren, Wheeler, Jasmine, Hewlett, Mollie, Vanderhook, Richard, Nowak, Daniel, Dicapua, Benison, Keung, Aditya, Kumar, Huned, Patwa, Kimberly, Robeson, Irene, Yang, Joan, Nye, and Hong, Vu
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Clinical Neurology ,Antibodies, Monoclonal, Humanized ,Placebo ,Article ,Antibodies ,Post-intervention ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Refractory ,law ,Internal medicine ,Monoclonal ,Myasthenia Gravis ,Medicine and Health Sciences ,Humans ,Medicine ,Humanized ,Science & Technology ,business.industry ,Middle Aged ,Eculizumab ,Complement Inactivating Agents ,Female ,Treatment Outcome ,EFFICACY ,medicine.disease ,Myasthenia gravis ,Clinical trial ,030104 developmental biology ,SAFETY ,Neurosciences & Neurology ,Neurology (clinical) ,business ,Life Sciences & Biomedicine ,COMPLEMENT INHIBITOR ECULIZUMAB ,030217 neurology & neurosurgery ,medicine.drug - Abstract
ObjectiveTo evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension.MethodsPatients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study.ResultsA total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1–4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected.ConclusionEculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population.ClinicalTrials.gov IdentifierREGAIN, NCT01997229; REGAIN open-label extension, NCT02301624.Classification of EvidenceThis study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo.
- Published
- 2020
74. RNA-sequencing and mass-spectrometry proteomic time-series analysis of T-cell differentiation identified multiple splice variants models that predicted validated protein biomarkers in inflammatory diseases
- Author
-
Sandra Hellberg, Olof Rundquist, Ingrid Kockum, Fredrik Piehl, Rasmus Magnusson, Jan Ernerudh, Johan Mellergård, Min Jung Kim, Mika Gustafsson, Maria C. Jenmalm, Mikael Benson, Chan Hyun Na, Maja Jagodic, David Gomez-Cabrero, Min-Sik Kim, Colm E Nestor, Claudio Altafini, and Jesper Tegnér
- Subjects
Bioinformatics and Systems Biology ,Protein biomarkers ,Chemistry ,T cell differentiation ,RNA ,splice ,Sample preparation ,Bioinformatik och systembiologi ,Computational biology ,proteomics ,RNA-seq ,T-cell differentiation ,biomarkers ,multiple sclerosis ,Mass spectrometry ,Proteomics - Abstract
Profiling of mRNA expression is an important method to identify biomarkers but complicated by limited correlations between mRNA expression and protein abundance. We hypothesised that these correlations could be improved by mathematical models based on measuring splice variants and time delay in protein translation. We characterised time-series of primary human naive CD4(+) T cells during early T helper type 1 differentiation with RNA-sequencing and mass-spectrometry proteomics. We performed computational time-series analysis in this system and in two other key human and murine immune cell types. Linear mathematical mixed time delayed splice variant models were used to predict protein abundances, and the models were validated using out-of-sample predictions. Lastly, we re-analysed RNA-seq datasets to evaluate biomarker discovery in five T-cell associated diseases, further validating the findings for multiple sclerosis (MS) and asthma. The new models significantly out-performing models not including the usage of multiple splice variants and time delays, as shown in cross-validation tests. Our mathematical models provided more differentially expressed proteins between patients and controls in all five diseases. Moreover, analysis of these proteins in asthma and MS supported their relevance. One marker, sCD27, was validated in MS using two independent cohorts for evaluating response to treatment and disease prognosis. In summary, our splice variant and time delay models substantially improved the prediction of protein abundance from mRNA expression in three different immune cell types. The models provided valuable biomarker candidates, which were further validated in MS and asthma. Funding Agencies|Swedish foundation for strategic research; Swedish Cancer Society [SB16-0011]; East Gothia Regional Funding [CAN 2017/625]; ake Wiberg foundation; Neuro Sweden; Swedish Research Council; National Research Foundation of Korea [2015-02575, 2015-03495, 2015-03807, 2016-07108, 2018-02776]; [NRF-2016K1A3A1A47921601]; [2017M3C7A1027472]
- Published
- 2022
75. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
- Author
-
Simon Englund, Marie Kierkegaard, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Elisa Longinetti, Thomas Frisell, and Fredrik Piehl
- Subjects
Multiple sclerosis ,Quality of life ,Neurologi ,Neurology ,Health-related quality of life ,Immunology ,Immunologi ,Cohort studies ,Comorbidity ,Fatigue ,Neurology (clinical) ,General Medicine - Abstract
Background: Fatigue is a debilitating symptom of multiple sclerosis (MS), but its relation to sociodemographic and disease-related characteristics has not been investigated in larger studies. The objectives of this study were to evaluate predictors of self-reported fatigue in a Swedish nationwide register-based MS cohort.Methods: Using a repeated cross-sectional design, we included 2,165 persons with relapsing-remitting and secondary progressive MS with one or multiple Fatigue Scale for Motor and Cognitive Functions (FSMC) scores, which was modelled using multivariable linear regressions for multiple predictors.Results: Only associations to expanded disability status scale (EDSS) and Symbol Digit Modalities Test (SDMT) were considered clinically meaningful among MS-associated characteristics in our main model; compared to mild disability (EDSS 0-2.5), those with severe disability (EDSS >= 6) scored 17.6 (95% CI 13.1-22.2) FSMC points higher, while the difference was 10.7 (95% CI 8.0-13.4) points for the highest and lowest quartiles of SDMT. Differences between highest and lowest quartiles of health-related quality of life (HRQoL) instruments were even greater and considered clinically meaningful; EuroQoL Visual Analogue Scale (EQ-VAS) 31.9 (95% CI 29.9-33.8), Multiple Sclerosis Impact Scale (MSIS-29) psychological component 35.6 (95% CI 33.8-37.4) and MSIS-29 physical component 45.5 (95% CI 43.7-47.4).Conclusion: Higher self-reported fatigue is associated with higher disability level and worse cognitive processing speed, while associations to other MS-associated characteristics including MS type, line of disease modifying therapy (DMT), MS duration, relapse and new cerebral lesions are weak. Furthermore, we found a strong correlation between high fatigue rating and lower ratings on health-related quality of life instruments. Funding Agencies|Patient-Centered Outcomes Research Institute (PCORI) Award [MS-1511-33196]; Swedish Research Council [2020-02700, TF 2016-01355]; Swedish Research Council for Health, Working Life, and Welfare [2020-0115]; NEURO Sweden
- Published
- 2022
76. Association between brain volume and disability over time in multiple sclerosis
- Author
-
Thomas, Moridi, Leszek, Stawiarz, Kyla A, McKay, Benjamin V, Ineichen, Russell, Ouellette, Daniel, Ferreira, J-Sebastian, Muehlboeck, Eric, Westman, Ingrid, Kockum, Tomas, Olsson, Fredrik, Piehl, Jan, Hillert, Ali, Manouchehrinia, and Tobias, Granberg
- Abstract
Most previous multiple sclerosis (MS) brain atrophy studies using MS impact scale 29 (MSIS-29) or symbol digit modalities test (SDMT) have been cross-sectional with limited sets of clinical outcomes.To investigate which brain and lesion volume metrics show the strongest long-term associations with the expanded disability status scale (EDSS), SDMT, and MSIS-29, and whether MRI-clinical associations vary with age.We acquired MRI and clinical data from a real-world Swedish MS cohort. FreeSurfer and SPM Lesion Segmentation Tool were used to obtain brain parenchymal, cortical and subcortical grey matter, thalamic and white matter fractions as well as TWe included 989 persons with MS followed for a median of 9.3 (EDSS), 10.1 (SDMT), and 9.3 (MSIS-29) years, respectively. In a cross-sectional analysis, the strength of the associations of the MRI metrics with the EDSS and MSIS-29 was found to drastically increase after 40-50 years of age. Low baseline regional grey matter fractions were associated with longitudinal increase of EDSS and physical MSIS-29 scores and decrease in SDMT scores and these atrophy measures were stronger predictors than the lesion volumes.The strength of MRI-clinical associations increase with age. Grey matter volume fractions are stronger predictors of long-term disability measures than lesion volumes.
- Published
- 2022
77. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
- Author
-
Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundström, Martin Gunnarsson, Rune Johansson, Johan Mellergård, Igal Rosenstein, Ahmad Ayad, Irina Sjöblom, Anette Risedal, Pierre de Flon, Eric Gilland, Jonas Lindeberg, Fadi Shawket, Fredrik Piehl, and Jan Lycke
- Subjects
Adult ,Sweden ,Young Adult ,Multiple Sclerosis ,Multiple Sclerosis, Relapsing-Remitting ,Adolescent ,Recurrence ,Dimethyl Fumarate ,Humans ,Neurology (clinical) ,Middle Aged ,Rituximab ,Immunosuppressive Agents - Abstract
B-cell depleting therapies are highly efficacious in relapsing-remitting multiple sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no phase 3 trial data are available. We therefore examined the safety and efficacy of rituximab compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis to obtain data that might allow inclusion of rituximab in treatment guidelines.RIFUND-MS was a multicentre, rater-blinded, active-comparator, phase 3, randomised controlled trial done at 17 Swedish university and community hospitals. Key inclusion criteria for participants were: age 18-50 years; relapsing-remitting multiple sclerosis or clinically isolated syndrome according to prevailing McDonald criteria; 10 years or less since diagnosis; untreated or only exposed to interferons or glatiramer acetate; and with clinical or neuroradiological disease activity in the past year. Patients were automatically randomly assigned (1:1) by the treating physician using a randomisation module in the Swedish multiple sclerosis registry, without stratification, to oral dimethyl fumarate 240 mg twice daily or to intravenous rituximab 1000 mg followed by 500 mg every 6 months. Relapse evaluation, Expanded Disability Status Scale rating, and assessment of MRI scans were done by examining physicians and radiologists masked to treatment allocation. The primary outcome was the proportion of patients with at least one relapse (defined as subacute onset of new or worsening neurological symptoms compatible with multiple sclerosis with a duration of more than 24 h and preceded by at least 30 days of clinical stability), assessed in an intention-to-treat analysis using log-binomial regression with robust standard errors. This trial is registered at ClinicalTrials.gov, NCT02746744.Between July 1, 2016, and Dec 18, 2018, 322 patients were screened for eligibility, 200 of whom were randomly assigned to a treatment group (100 assigned to rituximab and 100 assigned to dimethyl fumarate). The last patient completed 24-month follow-up on April 21, 2021. 98 patients in the rituximab group and 97 patients in the dimethyl fumarate group were eligible for the primary outcome analysis. Three (3%) patients in the rituximab group and 16 (16%) patients in the dimethyl fumarate group had a protocol-defined relapse during the trial, corresponding to a risk ratio of 0·19 (95% CI 0·06-0·62; p=0·0060). Infusion reactions (105 events [40·9 per 100 patient-years]) in the rituximab group and gastrointestinal reactions (65 events [47·4 per 100 patient-years]) and flush (65 events [47·4 per 100 patient-years]) in the dimethyl fumarate group were the most prevalent adverse events. There were no safety concerns.RIFUND-MS provides evidence that rituximab given as 1000 mg followed by 500 mg every 6 months is superior to dimethyl fumarate in preventing relapses over 24 months in patients with early relapsing-remitting multiple sclerosis. Health economic and long-term safety studies of rituximab in patients with multiple sclerosis are needed.Swedish Research Council.
- Published
- 2022
78. Author response: Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
- Author
-
Can Cui, Caroline Ingre, Li Yin, Xia Li, John Andersson, Christina Seitz, Nicolas Ruffin, Yudi Pawitan, Fredrik Piehl, and Fang Fang
- Published
- 2022
79. Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
- Author
-
Erik Portelius, Fredrik Piehl, Kaj Blennow, Ulf Andreasson, Mats Tullberg, Karolina Minta, Anna Jeppsson, Eric Peter Thelin, Faiez Al Nimer, Henrik Zetterberg, and Gunnar Brinkmalm
- Subjects
Adult ,Male ,medicine.medical_specialty ,Traumatic brain injury ,Science ,Matrix metalloproteinase ,Gastroenterology ,Article ,Extracellular matrix ,Medical research ,Cerebrospinal fluid ,Internal medicine ,Brain Injuries, Traumatic ,medicine ,Extracellular ,Humans ,Prospective Studies ,Aged ,Multidisciplinary ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Matrix Metalloproteinases ,Pathophysiology ,Neurology ,Case-Control Studies ,Magnetic bead ,(Idiopathic) normal pressure hydrocephalus ,Medicine ,Female ,business ,Biomarkers ,Follow-Up Studies ,Neuroscience - Abstract
Matrix metalloproteinases (MMPs) are extracellular enzymes involved in the degradation of extracellular matrix (ECM) proteins. Increased expression of MMPs have been described in traumatic brain injury (TBI) and may contribute to additional tissue injury and blood–brain barrier damage. The objectives of this study were to determine longitudinal changes in cerebrospinal fluid (CSF) concentrations of MMPs after acute TBI and in relation to clinical outcomes, with patients with idiopathic normal pressure hydrocephalus (iNPH) serving as a contrast group. The study included 33 TBI patients with ventricular CSF serially sampled, and 38 iNPH patients in the contrast group. Magnetic bead-based immunoassays were utilized to measure the concentrations of eight MMPs in ventricular human CSF. CSF concentrations of MMP-1, MMP-3 and MMP-10 were increased in TBI patients (at baseline) compared with the iNPH group (p
- Published
- 2020
80. Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis
- Author
-
Tobias Granberg, Fredrik Piehl, Susanne Neumann, Judith S. Brand, Thomas Moridi, Benjamin V. Ineichen, Martin Hlavica, University of Zurich, and Ineichen, Benjamin V
- Subjects
medicine.medical_specialty ,Pathology ,Magnetic Resonance Spectroscopy ,Neurology ,Imaging biomarker ,Clinical Neurology ,610 Medicine & health ,030218 nuclear medicine & medical imaging ,Multiple sclerosis ,03 medical and health sciences ,Magnetic resonance imaging ,0302 clinical medicine ,Atrophy ,10043 Clinic for Neuroradiology ,medicine ,Humans ,Cognitive Dysfunction ,Cognitive decline ,Neuroradiology ,Enlarged perivascular spaces ,Original Communication ,medicine.diagnostic_test ,business.industry ,Biomarker ,medicine.disease ,Meta-analysis ,2728 Neurology (clinical) ,2808 Neurology ,Systematic review ,Biomarker (medicine) ,Neurology (clinical) ,business ,Glymphatic System ,030217 neurology & neurosurgery - Abstract
Background Perivascular spaces can become detectable on magnetic resonance imaging (MRI) upon enlargement, referred to as enlarged perivascular spaces (EPVS) or Virchow-Robin spaces. EPVS have been linked to small vessel disease. Some studies have also indicated an association of EPVS to neuroinflammation and/or neurodegeneration. However, there is conflicting evidence with regards to their potential as a clinically relevant imaging biomarker in multiple sclerosis (MS). Methods To perform a systematic review and meta-analysis of EPVS as visualized by MRI in MS. Nine out of 299 original studies addressing EPVS in humans using MRI were eligible for the systematic review and meta-analysis including a total of 457 MS patients and 352 control subjects. Results In MS, EPVS have been associated with cognitive decline, contrast-enhancing MRI lesions, and brain atrophy. Yet, these associations were not consistent between studies. The meta-analysis revealed that MS patients have greater EPVS prevalence (odds ratio = 4.61, 95% CI = [1.84; 11.60], p = 0.001) as well as higher EPVS counts (standardized mean difference [SMD] = 0.46, 95% CI = [0.26; 0.67], p p = 0.01) compared to controls. Conclusions Available literature suggests a higher EPVS burden in MS patients compared to controls. The association of EPVS to neuroinflammatory or -degenerative pathology in MS remains inconsistent. Thus, there is currently insufficient evidence supporting EPVS as diagnostic and/or prognostic marker in MS. In order to benefit future comparisons of studies, we propose recommendations on EPVS assessment standardization in MS. PROSPERO No: CRD42019133946.
- Published
- 2020
81. Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
- Author
-
Praveen K. Chinthakindi, Elias S.J. Arnér, Belén Espinosa, Fredrik Piehl, Katarina Johansson, Per I. Arvidsson, Karl E. Carlström, and Faiez Al Nimer
- Subjects
0301 basic medicine ,Vinyl Compounds ,sulfoximine ,NF-E2-Related Factor 2 ,Central nervous system ,microglia ,Pharmacology ,multiple sclerosis ,Nrf2 ,redox regulation ,Pharmaceutical Sciences ,03 medical and health sciences ,chemistry.chemical_compound ,Myelin ,0302 clinical medicine ,In vivo ,pTRAF ,medicine ,Animals ,Humans ,HIF ,NF kappa B ,Pharmacology (medical) ,Sulfones ,Transcription factor ,dimethyl fumarate ,Dimethyl fumarate ,Microglia ,traumatic brain injury ,Multiple sclerosis ,Farmaceutiska vetenskaper ,medicine.disease ,In vitro ,Rats ,HEK293 Cells ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Original Article ,Neurology (clinical) ,030217 neurology & neurosurgery ,NFκB - Abstract
The Nrf2 transcription factor is a key regulator of redox reactions and considered the main target for the multiple sclerosis (MS) drug dimethyl fumarate (DMF). However, exploration of additional Nrf2-activating compounds is motivated, since DMF displays significant off-target effects and has a relatively poor penetrance to the central nervous system (CNS). We de novo synthesized eight vinyl sulfone and sulfoximine compounds (CH-1–CH-8) and evaluated their capacity to activate the transcription factors Nrf2, NFκB, and HIF1 in comparison with DMF using the pTRAF platform. The novel sulfoximine CH-3 was the most promising candidate and selected for further comparison in vivo and later an experimental model for traumatic brain injury (TBI). CH-3 and DMF displayed comparable capacity to activate Nrf2 and downstream transcripts in vitro, but with less off-target effects on HIF1 from CH-3. This was verified in cultured microglia and oligodendrocytes (OLs) and subsequently in vivo in rats. Following TBI, DMF lowered the number of leukocytes in blood and also decreased axonal degeneration. CH-3 preserved or increased the number of pre-myelinating OL. While both CH-3 and DMF activated Nrf2, CH-3 showed less off-target effects and displayed more selective OL associated effects. Further studies with Nrf2-acting compounds are promising candidates to explore potential myelin protective or regenerative effects in demyelinating disorders. Electronic supplementary material The online version of this article (10.1007/s13311-020-00855-0) contains supplementary material, which is available to authorized users.
- Published
- 2020
82. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
- Author
-
Katharina Fink, Joachim Burman, Anna Fogdell-Hahn, Petra Nilsson, Thomas Frisell, Peter Alping, Tomas Olsson, Jonatan Salzer, Martin Gunnarsson, Jan Lycke, Annette Langer-Gould, Johan Askling, Jan Hillert, Anders Svenningsson, Magnus Vrethem, and Fredrik Piehl
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Multiple Sclerosis ,Neurology ,Neurologi ,MEDLINE ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Natalizumab ,Neoplasms ,Internal medicine ,Humans ,Immunologic Factors ,Medicine ,Sweden ,Fingolimod Hydrochloride ,business.industry ,Incidence ,Kirurgi ,Multiple sclerosis ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Fingolimod ,030104 developmental biology ,Female ,Surgery ,Rituximab ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug ,Cohort study - Abstract
Objective: Novel, highly effective disease-modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. Methods: In this nationwide register-based cohort study, we linked data from the Swedish MS register to the Swedish Cancer Register and other national health care and census registers. We included 4,187 first-ever initiations of rituximab, 1,620 of fingolimod, and 1,670 of natalizumab in 6,136 MS patients matched for age, sex, and location to 37,801 non-MS general population subjects. Primary outcome was time to first invasive cancer. Results: We identified 78 invasive cancers among treated patients: rituximab 33 (incidence rate [IR] per 10,000 person-years = 34.4, 95% confidence interval [CI] = 23.7–48.3), fingolimod 28 (IR = 44.0, 95% CI = 29.2–63.5), and natalizumab 17 (IR = 26.0, 95% CI = 15.1–41.6). The general population IR was 31.0 (95% CI = 27.8–34.4). Adjusting for baseline characteristics, we found no difference in risk of invasive cancer between rituximab, natalizumab, and the general population but a possibly higher risk with fingolimod compared to the general population (hazard ratio [HR] = 1.53, 95% CI = 0.98–2.38) and rituximab (HR = 1.68, 95% CI = 1.00–2.84). Interpretation: In this first large comparative study of 3 highly effective MS disease-modifying therapies, no increased risk of invasive cancer was seen with rituximab and natalizumab, compared to the general population. However, there was a borderline-significant increased risk with fingolimod, compared to both the general population and rituximab. It was not possible to attribute this increased risk to any specific type of cancer, and further studies are warranted to validate these findings.
- Published
- 2020
83. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis
- Author
-
Irene Brusini, Michael Platten, Russell Ouellette, Fredrik Piehl, Chunliang Wang, and Tobias Granberg
- Subjects
Adult ,Male ,Multiple Sclerosis ,Reproducibility of Results ,Middle Aged ,Magnetic Resonance Imaging ,Corpus Callosum ,Deep Learning ,Image Processing, Computer-Assisted ,Humans ,Radiology, Nuclear Medicine and imaging ,Female ,Neurology (clinical) ,Atrophy - Abstract
Corpus callosum (CC) atrophy is predictive of future disability in multiple sclerosis (MS). However, current segmentation methods are either labor- or computationally intensive. We therefore developed an automated deep learning-based CC segmentation tool and hypothesized that its output would correlate with disability.A cohort of 631 MS patients (449 females, baseline age 41 ± 11 years) with both 3-dimensional T1-weighted and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI was used for the development. Data from 204 patients were manually segmented to train convolutional neural networks in extracting the midsagittal intracranial and CC areas. Remaining data were used to compare segmentations with FreeSurfer and benchmark the outputs with regard to clinical correlations. A 1.5 and 3 Tesla reproducibility cohort of 9 MS patients evaluated the segmentation robustness.The deep learning-based tool was accurate in selecting the appropriate slice for segmentation (98% accuracy within 3 mm of the manual ground truth) and segmenting the CC (Dice coefficient .88-.91) and intracranial areas (.97-.98). The accuracy was lower with higher atrophy. Reproducibility was excellent (intraclass correlation coefficient .90) for T1-weighted scans and moderate-good for FLAIR (.74-.75). Segmentations were associated with baseline and future (average follow-up time 6-7 years) Expanded Disability Status Scale (ρ = -.13 to -.24) and Symbol Digit Modalities Test (r = .18-.29) scores.We present a fully automatic deep learning-based CC segmentation tool optimized to modern imaging in MS with clinical correlations on par with computationally expensive alternatives.
- Published
- 2022
84. A Comparison of Brain Age Estimation And Brain Parenchymal Fraction as Imaging Markers in Multiple Sclerosis
- Author
-
Einar August Høgestøl, Tobias Kaufmann, Ann-Marie G. de Lange, Thomas Moridi, Russel Ouellette, Mads L. Pedersen, Benjamin Victor Ineichen, Dani Beck, Daniel Ferrerira, Sebastian Muehlboeck, Synne Brune, Gro Owren Nygaard, Pål Berg-Hansen, Mona Kristiansen Beyer, Piotr Sowa, Ali Manouchehrinia, Eric Westman, Tomas Olsson, Elisabeth Gulowsen Celius, Jan Hillert, Ingrid Skelton Kockum, Hanne Flinstad Harbo, Fredrik Piehl, Tobias Granberg, and Lars T. Westlye
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
85. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial
- Author
-
Fredrik, Piehl, Ann, Eriksson-Dufva, Anna, Budzianowska, Amalia, Feresiadou, William, Hansson, Max Albert, Hietala, Irene, Håkansson, Rune, Johansson, Daniel, Jons, Ivan, Kmezic, Christopher, Lindberg, Jonas, Lindh, Fredrik, Lundin, Ingela, Nygren, Anna Rostedt, Punga, Rayomand, Press, Kristin, Samuelsson, Peter, Sundström, Oskar, Wickberg, Susanna, Brauner, and Thomas, Frisell
- Subjects
Male ,Adolescent ,Neurologi ,Thymus Neoplasms ,Middle Aged ,Treatment Outcome ,Double-Blind Method ,Neurology ,Activities of Daily Living ,Myasthenia Gravis ,Quality of Life ,Humans ,Female ,Rituximab ,Aged - Abstract
IMPORTANCE Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown. OBJECTIVE To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG. DESIGN, SETTING, AND PARTICIPANTS This randomized, double-blind, placebo-controlled study took place throughout 48 weeks at 7 regional clinics in Sweden. Key inclusion criteria were age older than 18 years, onset of generalized symptoms within 12 months or less, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more. Patients were screened from October 20, 2016, to March 2, 2020. Key exclusion criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroid immunosuppressants or high doses of corticosteroids. INTERVENTIONS Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo. MAIN OUTCOMES AND MEASURES Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, 10 mg or less daily, and no rescue treatment. RESULTS Of 87 potentially eligible patients, 25 were randomized to rituximab (mean [SD] age, 67.4 [13.4] years; 7 [28%] female) and 22 to placebo (mean [SD] age, 58 [18.6] years; 7 [32%] female). Compared with placebo, a greater proportion with rituximab met the primary end point; 71% (17 of 24) in the rituximab group vs 29% (6 of 21) in the placebo group (Fisher exact test P = .007; probability ratio, 2.48 [95% CI, 1.20-5.11]). Secondary end points, comparing changes in Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life at 16 weeks with QMG at 24 weeks did not differ between groups with censoring for rescue treatment (per-protocol analysis) but were in favor of active treatment when rescue treatment was taken into account by worst rank imputation (post hoc analysis). Rescue treatments were also more frequent in the placebo arm (rituximab: 1 [4%]; placebo, 8 [36%]). One patient in the placebo arm had a myocardial infarction with cardiac arrest and 1 patient in the active arm experienced a fatal cardiac event. CONCLUSIONS AND RELEVANCE A single dose of 500 mg of rituximab was associated with greater probability of minimal MG manifestations and reduced need of rescue medications compared with placebo. Further studies are needed to address long-term benefit-risk balance with this treatment. Funding Agencies|Swedish Medical Research Council [2015-00887, 2020-02700]
- Published
- 2022
86. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis
- Author
-
Konrad Rejdak, Jeannette Lechner-Scott, Krzysztof Selmaj, Alessandra Solari, Eva Havrdova, Martin Vališ, Nektaria Alexandri, Raymond Hupperts, Fredrik Piehl, Bruno Brochet, Xavier Montalban, Birgit Keller, Axel Nolting, Dawn Langdon, Francesco Patti, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Klinische Neurowetenschappen, Institut Català de la Salut, [Brochet B] INSERM U 1215, University of Bordeaux, Bordeaux, France. [Hupperts R] Department of Psychology, Royal Holloway, University of London, Egham, United Kingdom. [Langdon D] Department of Psychology, Royal Holloway, University of London, Egham, United Kingdom. [Solari A] Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. [Piehl F] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. [Lechner-Scott J] University of Newcastle, Newcastle, NSW, Australia. Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Immunosuppressive Agents/adverse effects ,Personal Satisfaction ,Relapsing-Remitting ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,DISEASE ,Quality of life ,Cladribine tablets ,Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting [DISEASES] ,Prospective Studies ,Cladribine ,education.field_of_study ,Cumulative dose ,General Medicine ,enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente [ENFERMEDADES] ,Neurology ,Tolerability ,Local ,Patient Satisfaction ,Cohort ,Female ,Immunosuppressive Agents ,Qualitat de vida - Avaluació ,medicine.drug ,Tablets ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Pacients - Satisfacció ,Population ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Multiple Sclerosis, Relapsing-Remitting ,Internal medicine ,medicine ,Humans ,education ,Adverse effect ,Treatment satisfaction ,business.industry ,Multiple Sclerosis, Relapsing-Remitting/drug therapy ,Interim analysis ,Cladribine/adverse effects ,Neoplasm Recurrence ,Relapsing multiple sclerosis ,Quality of Life ,Neurology (clinical) ,Neoplasm Recurrence, Local ,business ,Esclerosi múltiple - Tractament ,Relapsing-Remitting/drug therapy - Abstract
Cladribine tablets; Relapsing multiple sclerosis; Treatment satisfaction Comprimidos de cladribina; Esclerosis múltiple recurrente; Satisfacción con el tratamiento Comprimits de cladribina; Esclerosi múltiple recurrent; Satisfacció amb el tractament Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) have been approved for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS). The ongoing CLARIFY-MS study (NCT03369665; EudraCT number: 2017-002632-17) aims to assess the effect of cladribine tablets 3.5 mg/kg on HRQoL of patients with highly active RMS. Objective To report on the design of the CLARIFY-MS study, baseline patient characteristics, and results of a pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability that includes all data reported till 6 months after start of treatment. Methods The CLARIFY-MS study is a 2-year, open-label, single-arm, prospective, multicenter, phase IV study. Eligible patients with highly active RMS were assigned to receive cladribine tablets 3.5 mg/kg over 2 years. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4; scale range from 0 to 100, higher values indicating higher satisfaction). Safety assessments, including occurrence of treatment-emergent adverse events (TEAEs; any adverse event reported after drug administration), serious adverse events (SAEs), and lymphocyte counts, were summarized descriptively. Results A total of 482 patients from 85 sites in Europe were treated with cladribine tablets. Mean patient age was 37.4 years, 338 (70.1%) were women, median EDSS was 2.5, and 345 (71.6%) were prior users of disease-modifying therapy (DMT). During the first 6 months after the start of treatment, and before reaching the full dose of cladribine tablets, mean TSQM global satisfaction score for the overall population was 70.4 (standard deviation, ± 18.48). The side effects score was 91.9 (± 17.68), convenience scored 86.6 (± 13.57), and effectiveness was 65.8 (± 21.14). A total of 275 patients (57.1%) reported at least one TEAE and 9 patients (1.9%) had a SAE. The majority of observed lymphopenia cases were of grade 1 or 2; 33 (6.8%) of the total study cohort had grade 3 lymphopenia, and no grade 4 lymphopenia was reported. Conclusion Patients reported high treatment satisfaction (TSQM) with cladribine tablets in this pre-planned interim analysis at 6 months. Few serious, and no unexpected, adverse events were reported, and there were no instances of grade 4 lymphopenia over the first 6 months. These preliminary data indicate good tolerability and convenience of administration of cladribine tablets in patients with highly active RMS. This study was sponsored by Merck Healthcare KGaA, Darmstadt, Germany
- Published
- 2022
87. Dilated Virchow-Robin Spaces are a Marker for Arterial Disease in Multiple Sclerosis
- Author
-
Benjamin V. Ineichen, Carmen Cananau, Michael Plattén, Russell Ouellette, Thomas Moridi, Katrin B. M. Frauenknecht, Serhat V. Okar, Zsolt Kulcsar, Ingrid Kockum, Fredrik Piehl, Daniel S. Reich, and Tobias Granberg
- Subjects
History ,Polymers and Plastics ,General Medicine ,Business and International Management ,General Biochemistry, Genetics and Molecular Biology ,Industrial and Manufacturing Engineering - Abstract
Virchow-Robin spaces (VRS) have been associated with neurodegeneration and neuroinflammation. However, it remains uncertain to what degree non-dilated or dilated VRS reflect specific features of neuroinflammatory pathology. Thus, we aimed at investigating the clinical relevance of VRS as imaging biomarker in multiple sclerosis (MS) and to correlate VRS to their histopathologic signature. In a cohort study comprising 205 MS patients (including a validation cohort) and 30 control subjects, we assessed the association of non-dilated and dilated VRS to clinical and magnetic resonance imaging (MRI) out-comes. Brain blocks from 6 MS patients and 3 non-MS controls were histopathologically processed to correlate VRS to their tissue substrate. The count of dilated centrum semiovale VRS was associated with increased T1 and T2 lesion volumes. There was no systematic spatial colocalization of dilated VRS with MS lesions. At tissue level, VRS mostly corresponded to arteries and were not associated with MS pathological hallmarks. Interestingly, dilated VRS in MS were associated with signs of small vessel disease. Contrary to prior beliefs, these observations suggest that VRS in MS do not associate with accumulation of immune cells. But instead, these findings indicate vascular pathology as a driver and/or consequence of neuroinflammatory pathology for this imaging feature.
- Published
- 2022
88. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
- Author
-
Pascal Benkert, Stephanie Meier, Sabine Schaedelin, Ali Manouchehrinia, Özgür Yaldizli, Aleksandra Maceski, Johanna Oechtering, Lutz Achtnichts, David Conen, Tobias Derfuss, Patrice H Lalive, Christian Mueller, Stefanie Müller, Yvonne Naegelin, Jorge R Oksenberg, Caroline Pot, Anke Salmen, Eline Willemse, Ingrid Kockum, Kaj Blennow, Henrik Zetterberg, Claudio Gobbi, Ludwig Kappos, Heinz Wiendl, Klaus Berger, Maria Pia Sormani, Cristina Granziera, Fredrik Piehl, David Leppert, Jens Kuhle, Stefanie Aeschbacher, Muhamed Barakovic, Andreas Buser, Andrew Chan, Giulio Disanto, Marcus D'Souza, Renaud Du Pasquier, Oliver Findling, Riccardo Galbusera, Kevin Hrusovsky, Michael Khalil, Johannes Lorscheider, Amandine Mathias, Annette Orleth, Ernst-Wilhelm Radue, Reza Rahmanzadeh, Tim Sinnecker, Suvitha Subramaniam, Jochen Vehoff, Sven Wellmann, Jens Wuerfel, Chiara Zecca, and Laboratory Medicine
- Subjects
Multiple Sclerosis ,Neurofilament Proteins ,Disease Progression ,Intermediate Filaments ,Humans ,Neurology (clinical) ,Multiple Sclerosis, Chronic Progressive ,Biomarkers ,Retrospective Studies - Abstract
Background: Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies. Methods: For derivation of a reference database of sNfL values, a control group was created, comprising participants with no evidence of CNS disease taking part in four cohort studies in Europe and North America. We modelled the distribution of sNfL concentrations in function of physiological age-related increase and BMI-dependent modulation, to derive percentile and Z score values from this reference database, via a generalised additive model for location, scale, and shape. We tested the reference database in participants with multiple sclerosis in the Swiss Multiple Sclerosis Cohort (SMSC). We compared the association of sNfL Z scores with clinical and MRI characteristics recorded longitudinally to ascertain their respective disease prognostic capacity. We validated these findings in an independent sample of individuals with multiple sclerosis who were followed up in the Swedish Multiple Sclerosis registry. Findings: We obtained 10 133 blood samples from 5390 people (median samples per patient 1 [IQR 1–2] in the control group). In the control group, sNfL concentrations rose exponentially with age and at a steeper increased rate after approximately 50 years of age. We obtained 7769 samples from 1313 people (median samples per person 6·0 [IQR 3·0–8·0]). In people with multiple sclerosis from the SMSC, sNfL percentiles and Z scores indicated a gradually increased risk for future acute (eg, relapse and lesion formation) and chronic (disability worsening) disease activity. A sNfL Z score above 1·5 was associated with an increased risk of future clinical or MRI disease activity in all people with multiple sclerosis (odds ratio 3·15, 95% CI 2·35–4·23; p
- Published
- 2022
- Full Text
- View/download PDF
89. Neuro‐COVID: Does severe COVID‐19 infection increase the risk for cognitive impairment?
- Author
-
Göran Hagman, Charlotta Thunborg, Pia Andersen, Nicholas Levak, Malin Aspö, Håkan Walles, Elias Jokhader, Jessica Kåhlin, David Nelson, Fredrik Piehl, Antonios Tzortzakakis, Henrik Zetterberg, Tobias Granberg, Lars I Eriksson, and Miia Kivipelto
- Subjects
Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Epidemiology ,Health Policy ,Neurology (clinical) ,Geriatrics and Gerontology - Published
- 2021
90. Structural Magnetic Resonance Imaging Findings and Histopathological Correlations in Human and Animal Motor Neuron Diseases – A Systematic Review and Meta-Analysis
- Author
-
Charlotte Zejlon, Dominik Nakhostin, Sebastian Winklhofer, Athina Pangalu, Sebastian Lewandowski, Johannes Finnsson, Fredrik Piehl, Caroline Ingre, Tobias Granberg, and Benjamin Victor Ineichen
- Abstract
Background: The lack of systematic evidence on neuroimaging findings in motor neuron diseases (MND) such as amyotrophic lateral sclerosis (ALS) hampers the diagnostic utility of magnetic resonance imaging (MRI) in the clinical setting. Moreover, it is unknown how well MND animal models mimic actual human neuroimaging features.Objective: To perform a systematic review and meta-analysis of MRI features in MND and corresponding animal models including their histopathological correlation.Methods: In a comprehensive literature search in Medline, Scopus, and Embase, out of 5941 unique publications, 223 records assessing brain and spinal cord MRI findings in MND were eligible for a qualitative synthesis. Of these, 21 records were included in a random effect model meta-analysis. For the animal systematic review, out of 175 unique publications, 33 records assessed neuroimaging findings in MND animal models. Data mining techniques were exploited for risk of bias assessment.Results: T2-hyperintensities along the corticospinal tract as well as motor cortex T2*-hypointensities, also termed the “motor band sign”, were among the most commonly assessed imaging biomarkers. Our meta-analysis shows that both T2-hyperintensities along the corticospinal tracts and the motor band sign more commonly occur in ALS patients compared to controls (Odds ratio 2.21 [95%-CI: 1.40-3.49] and 10.85 [95%-CI: 3.74-31.44], respectively). Evidence from a limited number of studies suggest these two imaging findings to correlate to focal axonal degeneration/myelin pallor or glial iron deposition on histopathology. Whole brain or regional central nervous system (CNS) atrophy was also frequently assessed. Clinical MND phenotypes such as ALS versus ALS-frontotemporal dementia seem to present with distinct CNS atrophy patterns. Furthermore, certain MRI imaging findings in MND animal models such as brain volume loss show partial resemblance with corresponding human imaging features.Conclusions: Multiple corroborating studies support the notion that MND in humans can be distinguished based on certain MRI features, which also correlate to neuropathological findings. In addition, there is also some overlap with findings in animal MND models. Collectively, this study provides high-grade evidence for the usefulness of MRI in the diagnostic workup of suspected MND cases. Further studies are needed to address the value of MRI for a more exact definition of MND subtypes and prognosticating the disease course.Trial registration number: CRD42020182682
- Published
- 2021
91. Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls
- Author
-
Andreas Wallin, Erika Franzén, Lucian Bezuidenhout, Urban Ekman, Fredrik Piehl, and Sverker Johansson
- Subjects
Multiple Sclerosis ,Cognition ,Neurology ,Case-Control Studies ,Task Performance and Analysis ,Humans ,Walking ,Neurology (clinical) ,General Medicine ,Gait - Abstract
Reduced motor and cognitive dual-task capacity is found to be more common among people with multiple sclerosis (MS), than among healthy populations. However, studies in larger samples of MS conducted using a more stringent methodology, which includes comparisons to healthy controls, are needed. Thus, the primary aim of this study was to explore the effects on motor and cognitive dual-tasking in people with mild to moderate overall MS-disability, in comparison to healthy controls. A second aim was to explore the differences in dual-task performance on a cognitive task between two motor tasks in people with mild to moderate MS and healthy controls.This case-control study evaluated dual-task performance of the motor tasks standing with eyes closed (hereafter standing) and walking and a cognitive task assessing selective executive functions (auditory-Stroop test). Fifty-five people with MS (mild MS, n = 28; moderate MS, n = 27), and 30 healthy controls participated. Standing and walking were assessed using wireless inertial measurement unit sensors (APDM). Standing (three 30 s trials) was measured using sway area and root mean square sway, while walking (2 min) was measured using speed, stride length, and step time. Auditory-Stroop was measured using accuracy and response time. During dual-task assessments, each subject was instructed to pay equal attention to both tasks. Statistical significance was considered if p .05.Instanding no significant within-group differences in the standing measures were found between single-task and dual-task performance. However, dual-task performance differed significantly between all groups (moderate MSmild MShealthy controls), except between mild and moderate MS in sway area. Inwalking, all groups slowed down speed and shortened stride length during dual-task condition compared to single-task condition. Moderate MS performed significantly poorer than mild MS and healthy controls in dual-task walking, but mild MS did not differ from healthy controls. In thecognitivetask only mild MS increased significantly in auditory-Stroop response time during walking. In healthy controls, the performance of auditory-Stroop was not affected by dual-tasking. Moderate MS had significantly longer response time in dual-task auditory-Stroop compared to the other groups, but no differences were observed between mild MS and healthy controls. Only mild MS had significantly longer response time during walking than during standing.This study showed that cognitive-motor interference in people with MS is present also in the early phases of the disease. This was shown during dual-tasking with slower walking and a longer response time in the cognitive task compared to healthy controls. Moderate MS performed poorer in almost every aspect of the motor and cognitive assessments in dual-task condition, compared to mild MS and healthy controls. Furthermore, during standing, people with MS performed poorer in standing measures compared to healthy controls. Additionally, healthy controls showed no cognitive interference during motor tasks. The results suggest that standardized regular assessment of dual-tasking in MS care might increase the individual's knowledge of dual-task capacity and contribute to understanding of possible related consequences. However, feasible assessment equipment and specific motor-cognitive dual-task training interventions for people with MS need to be developed.
- Published
- 2022
92. Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings
- Author
-
Scott Montgomery, Kelsi A Smith, Ayako Hiyoshi, Fredrik Piehl, Katja Fall, Tomas Olsson, and Yin Xu
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Multiple Sclerosis ,Mononucleosis ,Adolescent ,Population ,Cohort Studies ,Young Adult ,Risk Factors ,Medicine ,Humans ,Infectious Mononucleosis ,Risk factor ,Young adult ,education ,Child ,Proportional Hazards Models ,Original Investigation ,Sweden ,education.field_of_study ,business.industry ,Multiple sclerosis ,Siblings ,Research ,Hazard ratio ,Confounding ,General Medicine ,medicine.disease ,Online Only ,Neurology ,Female ,business ,Cohort study - Abstract
Key Points Question Is diagnosis of infectious mononucleosis (IM) in childhood or adolescence associated with subsequent development of multiple sclerosis (MS)? Findings In this population–based cohort study of 2 492 980 individuals in Sweden, IM in childhood and adolescence was associated with an increased risk of a subsequent MS diagnosis that remained significant after controlling for measured and unmeasured shared familial factors. Meaning These findings suggest that IM in childhood and particularly adolescence is a risk factor for a subsequent MS diagnosis, independent of shared familial factors, making it less likely that greater susceptibility to infection is the explanation., This cohort study assesses the association of hospital-diagnosed infectious mononucleosis in childhood and adolescence with risk of a multiple sclerosis diagnosis in young adults using national population registers in Sweden., Importance Epstein-Barr virus and its acute manifestation, infectious mononucleosis (IM), are associated with an increased risk of multiple sclerosis (MS). Whether this association is confounded by susceptibility to infection is still debated. Objective To assess whether hospital-diagnosed IM during childhood, adolescence, or young adulthood is associated with subsequent MS diagnosis independent of shared familial factors. Design, Setting, and Participants This population–based cohort study used the Swedish Total Population Register to identify individuals born in Sweden from January 1, 1958, to December 31, 1994. Participants aged 20 years were followed up from January 1, 1978, to December 31, 2018, with a median follow-up of 15.38 (IQR, 8.68-23.55; range, 0.01-40.96) years. Data were analyzed from October 2020 to July 2021. Exposure Hospital-diagnosed IM before 25 years of age. Main Outcomes and Measures Diagnoses of MS from 20 years of age were identified. Risk of an MS diagnosis associated with IM in childhood (birth to 10 years of age), adolescence (11-19 years of age), and early adulthood (20-24 years of age [time-dependent variable]) were estimated using conventional and stratified (to address familial environmental or genetic confounding) Cox proportional hazards regression. Results Of the 2 492 980 individuals (1 312 119 men [52.63%] and 1 180 861 women [47.37%]) included, 5867 (0.24%) had an MS diagnosis from 20 years of age (median age, 31.50 [IQR, 26.78-37.54] years). Infectious mononucleosis in childhood (hazard ratio [HR], 1.98; 95% CI, 1.21-3.23) and adolescence (HR, 3.00; 95% CI, 2.48-3.63) was associated with an increased risk of an MS diagnosis that remained significant after controlling for shared familial factors in stratified Cox proportional hazards regression (HRs, 2.87 [95% CI, 1.44-5.74] and 3.19 [95% CI, 2.29-4.46], respectively). Infectious mononucleosis in early adulthood was also associated with risk of a subsequent MS diagnosis (HR, 1.89; 95% CI, 1.18-3.05), but this risk was attenuated and was not significant after controlling for shared familial factors (HR, 1.51; 95% CI, 0.82-2.76). Conclusions and Relevance These findings suggest that IM in childhood and particularly adolescence is a risk factor associated with a diagnosis of MS, independent of shared familial factors.
- Published
- 2021
93. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis: a longitudinal cohort study
- Author
-
Fredrik Piehl, Can Cui, Xia Li, Yudi Pawitan, Christina Seitz, Caroline Ingre, John Andersson, Nicolas Ruffin, Li Yin, and Fang Fang
- Subjects
Oncology ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,T cell ,Lower risk ,medicine.disease ,Immune system ,medicine.anatomical_structure ,Internal medicine ,Epidemiology ,medicine ,Clinical significance ,Amyotrophic lateral sclerosis ,business ,CD8 - Abstract
BackgroundImmune response changes have been reported in amyotrophic lateral sclerosis (ALS), but their clinical relevance remains undetermined. Therefore, we aim to evaluate the relationships between blood leukocyte subpopulations and prognosis of ALS.MethodsA longitudinal cohort of 288 ALS patients with up to 5 years of follow-up during 2015-2020 were recruited at the only tertiary referral center for ALS in Stockholm, Sweden. Routine differential leukocyte counts, and determination of lymphocyte subpopulations including an extended T cell panel with flow cytometry, collected at diagnosis and at regular intervals thereafter. The primary outcome was risk of death (alternatively use of invasive ventilation) after diagnosis of ALS. The secondary outcomes included repeatedly measured functional status - through Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) score and disease progression rate. Cox model was used to evaluate the associations between leukocytes and risk of death. Generalized estimating equation model (GEE) was used to assess the correlation between leukocytes and ALSFRS-R score and disease progression rate.ResultsThe counts of leukocytes, neutrophils and monocytes increased gradually over time since diagnosis and were negatively correlated with ALSFRS-R score, but not associated with risk of death or disease progression rate. Focusing on lymphocyte subpopulations, increasing counts of natural killer (NK) cells (HR=0.61, 95% CI= [0.42-0.88] per SD increase) and proportions of Th2-diffrentiated CD4+ central memory (CM) T cells (HR=0.64, 95% CI= [0.48-0.85] per SD increase) were correlated with a lower risk of death. Increasing proportions of CD4+ effector memory cells re-expressing CD45RA (EMRA) T cells (HR=1.39, 95% CI= [1.01-1.92] per SD increase) and CD8+ T cells (HR=1.38, 95% CI= [1.03-1.86] per SD increase) were associated with a higher risk of death. None of the lymphocyte subpopulations was correlated with ALSFRS-R score or disease progression rate.ConclusionOur findings suggest a dual role of immune responses in ALS prognosis, where neutrophils and monocytes primarily reflect functional status whereas NK cells and different T lymphocyte populations act as prognostic markers for survival. The findings also provide insights for cell-specific treatment for ALS.FundingThis work was supported by the European Research Council (ERC) Starting Grant (MegaALS, No. 802091), the Swedish Research Council (No. 2019-01088), Karolinska Institutet (Strategic Research Area in Epidemiology and Senior Researcher Award), and China Scholarship Council.
- Published
- 2021
94. Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
- Author
-
Jesse, Huang, Mohsen, Khademi, Örjan, Lindhe, Gunn, Jönsson, Fredrik, Piehl, Tomas, Olsson, and Ingrid, Kockum
- Subjects
Proteomics ,Multiple Sclerosis ,Time Factors ,Centrifugation ,CSF ,CNS, central nervous system ,CSF, cerebrospinal fluid ,Specimen Handling ,MS, multiple sclerosis ,SIRT2, sirtuin 2 ,blood ,Humans ,CD40L, cluster differentiation 40 ligand ,plasma ,Inflammation ,PEA, proximity extension assay ,Research ,Cerebrospinal Fluid Proteins ,Blood Proteins ,IL, interleukin ,CXCL, C-X-C motif chemokine ,proximity extension assay ,RT, room temperature ,AXIN-1, axis inhibitor 1 ,Gompertz function ,Biomarkers - Abstract
Proteomics studies are important for the discovery of new biomarkers as clinical tools for diagnosis and disease monitoring. However, preanalytical variations caused by differences in sample handling protocol pose challenges for assessing biomarker reliability and comparability between studies. The purpose of this study was to examine the effects of delayed centrifuging on measured protein levels in plasma and cerebrospinal fluid (CSF). Blood from healthy individuals and patients with multiple sclerosis along with CSF from patients with suspected neurological disorders were left at room temperature for different periods (blood: 1, 24, 48, 72 h; CSF: 1 and 6 h) prior to centrifuging. Ninety-one inflammation-related proteins were analyzed using a proximity extension assay, a high-sensitivity multiplex immunoassay. Additional metabolic and neurology-related markers were also investigated in CSF. In summary, many proteins, particularly in plasma, had increased levels with longer delays in processing likely due in part to intracellular leakage. Levels of caspase 8, interleukin 8, interleukin 18, sirtuin 2, and sulfotransferase 1A1 increased 2-fold to 10-fold in plasma after 24 h at room temperature. Similarly, levels of cathepsin H, ectonucleoside triphosphate diphosphohydrolase 5, and WW domain containing E3 ubiquitin protein ligase 2 differentiated in CSF with, Graphical Abstract, Highlights • Several blood and cerebrospinal fluid proteins are affected by sample handling. • Plasma protein levels increased with longer centrifugation delay from hemolysis. • Certain proteins may assess sample handling variability and predict delay time., In Brief We assessed the effects of delayed sample handling on a panel of 92 inflammation-related proteins in the blood and cerebrospinal fluid. Plasma protein levels were measured at delayed centrifugation times of 1, 24, 48, and 72 h corresponding with common postal-transit delays, and changes in relative concentration were modeled and validated using an external dataset. Several proteins were selected as markers of assessing sample handling variability for application in future studies.
- Published
- 2021
95. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
- Author
-
Can, Cui, Caroline, Ingre, Li, Yin, Xia, Li, John, Andersson, Christina, Seitz, Nicolas, Ruffin, Yudi, Pawitan, Fredrik, Piehl, and Fang, Fang
- Subjects
Phenotype ,Amyotrophic Lateral Sclerosis ,Disease Progression ,Leukocytes ,Humans ,Longitudinal Studies ,CD8-Positive T-Lymphocytes - Abstract
The prognostic role of immune cells in amyotrophic lateral sclerosis (ALS) remains undetermined. Therefore, we conducted a longitudinal cohort study including 288 ALS patients with up to 5-year follow-up during 2015-2020 recruited at the only tertiary referral center for ALS in Stockholm, Sweden, and measured the levels of differential leukocytes and lymphocyte subpopulations. The primary outcome was risk of death after diagnosis of ALS and the secondary outcomes included functional status and disease progression rate. Cox model was used to evaluate the associations between leukocytes and risk of death. Generalized estimating equation model was used to assess the correlation between leukocytes and functional status and disease progression rate. We found that leukocytes, neutrophils, and monocytes increased gradually over time since diagnosis and were negatively correlated with functional status, but not associated with risk of death or disease progression rate. For lymphocyte subpopulations, NK cells (HR= 0.61, 95% CI = [0.42-0.88] per SD increase) and Th2-diffrentiated CD4
- Published
- 2021
96. Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia
- Author
-
Jessica Gracias, Funda Orhan, Elin Hörbeck, Jessica Holmén-Larsson, Neda Khanlarkani, Susmita Malwade, Sravan K. Goparaju, Lilly Schwieler, İlknur Ş. Demirel, Ting Fu, Helena Fatourus-Bergman, Aurimantas Pelanis, Carleton P. Goold, Anneli Goulding, Kristina Annerbrink, Anniella Isgren, Timea Sparding, Martin Schalling, Viviana A. Carcamo Yañez, Jens C. Göpfert, Johanna Nilsson, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Göran Engberg, Fredrik Piehl, Steven D. Sheridan, Roy H. Perlis, Simon Cervenka, Sophie Erhardt, Mikael Landen, and Carl M. Sellgren
- Subjects
Psychiatry ,Multidisciplinary ,Psychotic Disorders ,Risk Factors ,Schizophrenia ,General Physics and Astronomy ,Humans ,Complement C4a ,General Chemistry ,General Biochemistry, Genetics and Molecular Biology ,Psykiatri - Abstract
Postsynaptic density is reduced in schizophrenia, and risk variants increasing complement component 4A (C4A) gene expression are linked to excessive synapse elimination. In two independent cohorts, we show that cerebrospinal fluid (CSF) C4A concentration is elevated in patients with first-episode psychosis (FEP) who develop schizophrenia (FEP-SCZ: median 0.41 fmol/ul [CI = 0.34–0.45], FEP-non-SCZ: median 0.29 fmol/ul [CI = 0.22–0.35], healthy controls: median 0.28 [CI = 0.24–0.33]). We show that the CSF elevation of C4A in FEP-SCZ exceeds what can be expected from genetic risk variance in the C4 locus, and in patient-derived cellular models we identify a mechanism dependent on the disease-associated cytokines interleukin (IL)−1beta and IL-6 to selectively increase neuronal C4A mRNA expression. In patient-derived CSF, we confirm that IL-1beta correlates with C4A controlled for genetically predicted C4A RNA expression (r = 0.39; CI: 0.01–0.68). These results suggest a role of C4A in early schizophrenia pathophysiology.
- Published
- 2021
97. Cerebrospinal fluid concentration of complement component 4A is increased in first-episode schizophrenia
- Author
-
Jessica Holmén-Larsson, Susmita Malwade, Fredrik Piehl, Martin Schalling, Göran Engberg, Carleton Goold, Elin Hörbeck, Sravan K. Goparaju, Viviana A. Carcamo Yañez, Anniella Isgren, Roy H. Perlis, Sophie Erhardt, Timea Sparding, Neda Khanlarkani, Mikael Landén, Kristina Annerbrink, Lilly Schwieler, Aurimantas Pelanis, Anneli Goulding, Helena Fatourus-Bergman, Carl M. Sellgren, Jens C. Göpfert, Funda Orhan, Steven D. Sheridan, Ann Brinkmalm, Henrik Zetterberg, Kaj Blennow, Johanna Nilsson, Simon Cervenka, and Jessica Gracias
- Subjects
Synapse ,Psychosis ,Cerebrospinal fluid ,Schizophrenia ,business.industry ,Immunology ,C4A ,medicine ,medicine.disease ,business ,First episode schizophrenia ,Complement (complexity) - Abstract
Excessive synapse loss is a core feature of schizophrenia and is linked to the complement component 4A gene (C4A). In two independent cohorts, we show that cerebrospinal fluid (CSF) C4A concentration is elevated in first-episode psychosis patients who develop schizophrenia and correlates with CSF measurements of synapse density. Using patient-derived cellular modeling, we find that disease-associated cytokines increase neuronal C4A expression and that IL-1β associates with C4A in patient-derived CSF.
- Published
- 2021
98. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies
- Author
-
Jan Hillert, Fredrik Piehl, Tim Spelman, Finn Sellebjerg, Matthias Kant, Peter Vestergaard Rasmussen, Anders Svenningsson, Melinda Magyari, Jan Lycke, and Hanna Joensen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Denmark ,Danish ,Cohort Studies ,chemistry.chemical_compound ,Multiple Sclerosis, Relapsing-Remitting ,Internal medicine ,Teriflunomide ,Medicine ,Humans ,Registries ,Original Investigation ,Sweden ,Expanded Disability Status Scale ,business.industry ,Multiple sclerosis ,Hazard ratio ,Confounding ,Multiple Sclerosis, Relapsing-Remitting/drug therapy ,Middle Aged ,medicine.disease ,language.human_language ,Treatment Outcome ,chemistry ,Propensity score matching ,language ,Immunosuppressive Agents/therapeutic use ,Female ,Neurology (clinical) ,business ,Immunosuppressive Agents ,Cohort study - Abstract
Importance: Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The difference in the association of these national strategies with clinical outcomes is unknown. Objective: To investigate the association of national differences in disease-modifying treatment (DMT) strategies for RRMS with disability outcomes. Design, Setting, and Participants: This cohort study used data on 4861 patients from the Danish and Swedish national multiple sclerosis (MS) registries from the date of index DMT initiation (between January 1, 2013, and December 31, 2016) until the last recorded visit at time of data extraction (October 2, 2019). Exposures: All MS-specific DMTs initiated during the observation period were included in the analysis. Main Outcomes and Measures: The primary study outcome was time to 24-week confirmed disability worsening. Secondary outcomes were 24-week confirmed disability improvement, milestone Expanded Disability Status Scale scores of 3 and 4, annualized relapse rate, time to first relapse, and treatment switching. Data were analyzed using inverse probability of treatment weighting-based models using a propensity score to weight and correct the comparison for the imbalance of confounders observed at baseline between the 2 countries. Results: A total of 2700 patients from the Swedish MS registry (1867 women [69.2%]; mean [SD] age, 36.1 [9.5] years) and 2161 patients from the Danish MS registry (1472 women [68.1%]; mean [SD] age, 37.3 [9.4 years]) started a first DMT between 2013 and 2016, were included in the analysis, and were observed for a mean (SD) of 4.1 (1.5) years. A total of 1994 Danish patients (92.3%) initiated a low to moderately effective DMT (teriflunomide, 907 [42.0%]) and 165 (7.6%) initiated a highly effective DMT, whereas a total of 1769 Swedish patients (65.5%) initiated a low to moderately effective DMT (teriflunomide, 64 [2.4%]) and 931 (34.5%) initiated a highly effective DMT. The Swedish treatment strategy was associated with a 29% reduction in the rate of postbaseline 24-week confirmed disability worsening relative to the Danish treatment strategy (hazard ratio, 0.71; 95% CI, 0.57-0.90; P =.004). The Swedish treatment strategy was also associated with a 24% reduction in the rate of reaching an expanded disability status scale score of 3 (hazard ratio, 0.76; 95% CI, 0.60-0.97; P =.03) and a 25% reduction in the rate of reaching an expanded disability status scale score of 4 (hazard ratio, 0.75; 95% CI, 0.61-0.96; P =.01) relative to Danish patients. Conclusions and Relevance: The findings of this study suggest that there is an association between differences in treatment strategies for RRMS and disability outcomes at a national level. Escalation of treatment efficacy was inferior to using more efficacious DMT as initial treatment..
- Published
- 2021
99. Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
- Author
-
Fredrik Piehl and Thomas Mathew
- Subjects
Neurology ,Neurology (clinical) - Published
- 2022
100. Amélioration de la QoL à 1 an chez les patients traités par Cladribine comprimés pour une SEP récurrente très active : analyse intermédiaire de l’étude CLARIFY-MS
- Author
-
Alessandra Solari, Xavier Montalban, Jeannette Lechner-Scott, Fredrik Piehl, Bruno Brochet, and Birgit Keller
- Subjects
Neurology ,Neurology (clinical) - Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.